abmc_10q.htm

0001654954-23-007911.txt : 20230612 0001654954-23-007911.hdr.sgml : 20230612 20230612161911 ACCESSION NUMBER: 0001654954-23-007911 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230612 DATE AS OF CHANGE: 20230612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERICAN BIO MEDICA CORP CENTRAL INDEX KEY: 0000896747 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141702188 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-28666 FILM NUMBER: 231008331 BUSINESS ADDRESS: STREET 1: 122 SMITH ROAD CITY: KINDERHOOK STATE: NY ZIP: 12106 BUSINESS PHONE: 5187588158 MAIL ADDRESS: STREET 1: 122 SMITH ROAD CITY: KINDERHOOK STATE: NY ZIP: 12106 10-Q 1 abmc_10q.htm FORM 10-Q abmc_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

☒	Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For the quarterly period ended March 31, 2023

☐	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For the transition period from to

Commission File Number: 0-28666

AMERICAN BIO MEDICA CORPORATION

(Exact name of registrant as specified in its charter)

New York		14-1702188
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

122 Smith Road, Kinderhook, New York		12106
(Address of principal executive offices)		(Zip Code)

518-758-8158

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	ABMC	OTC Markets Pink

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files) ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ Yes ☒ No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

48,098,476 Common Shares as of June 12, 2023

American Bio Medica Corporation

Index to Quarterly Report on Form 10-Q

For the quarter ended March 31, 2023

		PAGE
PART I – FINANCIAL INFORMATION

Item 1.	Condensed Financial Statements	3
	Condensed Balance Sheets as of March 31, 2023 (unaudited) and December 31, 2022	3
	Condensed Unaudited Statements of Operations for the three months ended March 31, 2023 and March 31, 2022	4
	Statements of Changes in Stockholders’ Deficit for the three months ended March 31, 2023 and March 31, 2022	5
	Condensed Unaudited Statements of Cash Flows for the three months ended March 31, 2023 and March 31, 2022	6
	Notes to Condensed Financial Statements (unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23
Item 4.	Controls and Procedures	23

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	24
Item 4.	Mine Safety Disclosures	24
Item 5.	Other Information	24
Item 6.	Exhibits	25

Signatures		26

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Condensed Financial Statements

American Bio Medica Corporation
Condensed Balance Sheets
	March 31,			December 31,
	2023			2022
ASSETS	(Unaudited)
Current assets
Cash and cash equivalents	$	68,000		$	34,000
Accounts receivable, net of allowance for doubtful accounts of $2,000 at March 31, 2023 and at December 31, 2022		89,000			82,000
Inventory, net of allowance of $0 at March 31, 2023 and $235,000 at December 31, 2022		0			379,000
Employee retention credit receivable		202,000			202,000
Retention fund receivable-asset sale		300,000
Prepaid expenses and other current assets		0			72,000
Total current assets		659,000			769,000
Property, plant and equipment, net		0			466,000
Right of use asset – operating leases		0			13,000
Other assets		0			21,000
Total assets	$	659,000		$	1,269,000

LIABILITIES AND STOCKHOLDERS’ (DEFICIT)
Current liabilities
Accounts payable	$	572,000		$	760,000
Accrued expenses and other current liabilities		338,000			514,000
Right of use liability – operating leases		0			4,000
Wages payable		32,000			94,000
Current portion of long-term debt		175,000			2,230,000
Total current liabilities		1,117,000			3,602,000
Right of use liability – operating leases		0			6,000
Total liabilities		1,117,000			3,608,000
COMMITMENTS AND CONTINGENCIES
Stockholders' deficit:
Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at March 31, 2023 and December 31, 2022		0			0
Common stock; par value $.01 per share; 75,000,000 shares authorized; 48,098,476 issued and outstanding at March 31, 2023 and at December 31, 2022		481,000			481,000
Additional paid-in capital		22,403,000			22,403,000
Deficit		(23,342,000	)		(25,223,000	)
Total stockholders’ (deficit)		(458,000	)		(2,339,000	)
Total liabilities and stockholders’ (deficit)	$	659,000		$	1,269,000

The accompanying notes are an integral part of the condensed financial statements

Table of Contents

American Bio Medica Corporation
Condensed Statements of Operations
(Unaudited)
	For The Three Months Ended
	March 31,
	2023			2022

Net sales	$	164,000		$	351,000

Cost of goods sold		90,000			323,000

Gross profit		74,000			28,000

Operating expenses:
Research and development		28,000			22,000
Selling and marketing		20,000			42,000
General and administrative		238,000			295,000
		286,000			359,000

Operating loss		(212,000	)		(331,000	)

Other income/ (expense):
Loss on asset valuation		(921,000	)		0
Other income – asset sale		3,035,000			0
Interest expense		(21,000	)		(48,000	)
		2,093,000			(48,000	)

Net income / (loss) before tax		1,881,000			(379,000	)

Income tax expense		0			0

Net income / (loss)	$	1,881,000		$	(379,000	)

Basic and diluted income / (loss) per common share	$	0.04		$	(0.01	)

Weighted average number of shares outstanding – basic & diluted		48,098,476			47,770,698

The accompanying notes are an integral part of the condensed financial statements

Table of Contents

American Bio Medica Corporation
Statements of Changes in Stockholders’ Deficit
(Unaudited)

	Common Stock				Additional Paid-in
	Shares		Amount		Capital		Deficit			Total
Balance – January 1, 2023		48,098,476	$	481,000	$	22,403,000	$	(25,223,000	)	$	(2,339,000	)
Net income								1,881,000			1,881,000
Balance – March 31, 2023		48,098,476	$	481,000	$	22,403,000	$	(23,342,000	)	$	(458,000	)

Balance January 1, 2022		47,598,476	$	476,000	$	22,393,000	$	(22,813,000	)	$	(944,000	)
Shares issued in connection with Landmark consulting agreement		500,000		5,000		10,000					15,000
Net loss								(379,000	)		(379,000	)
Balance – March 31, 2022		48,098,476	$	481,000	$	22,403,000	$	(24,192,000	)	$	(1,308,000	)

Table of Contents

American Bio Medica Corporation
Condensed Statements of Cash Flows
(Unaudited)
	For The Three Months Ended
	March 31,
	2023			2022
Cash flows from operating activities:
Net income / (loss)	$	1,881,000		$	(379,000	)
Adjustments to reconcile net income / (loss) to net cash used in operating activities:
Depreciation and amortization		8,000			13,000
Asset Sale to Healgen		(2,114,000	)		0
Provision for bad debt		0			(1,000	)
Consulting fee paid with restricted stock		0			15,000
Changes in:
Accounts receivable		(7,000	)		186,000
Inventory		0			24,000
Prepaid expenses and other current assets		83,000			(11,000	)
Right of use asset		0			9,000
Accounts payable		24,000			161,000
Accrued expenses and other current liabilities		(176,000	)		(17,000	)
Right of use liability		0			(9,000	)
Wages payable		(62,000	)		(4,000	)
Net cash used in operating activities		(363,000	)		(13,000	)
Cash Flows from investing activities
Business Sale, net proceeds		247,000			0
Net cash provided by investing activities		247,000			0
Cash flows from financing activities:
Payments on debt financing		(100,000	)		0
Proceeds from debt financing		250,000			0
Proceeds from lines of credit		0			462,000
Payments on lines of credit		0			(547,000	)
Net cash provided by / (used in) financing activities		150,000			(85,000	)
Net change in cash and cash equivalents		34,000			(98,000	)
Cash and cash equivalents - beginning of period		34,000			115,000
Cash and cash equivalents - end of period	$	68,000		$	17,000
Supplemental disclosures of cash flow information
Non-Cash transactions:
Consulting fee paid with restricted stock	$	0		$	15,000
Cash paid for interest	$	41,000		$	46,000

The accompanying notes are an integral part of the condensed financial statements

Table of Contents

Notes to condensed financial statements (unaudited)

March 31, 2023

Note A - Basis of Reporting

The accompanying unaudited interim condensed financial statements of American Bio Medica Corporation (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Regulation S-X. Accordingly, these unaudited interim condensed financial statements do not include all information and footnotes required by U.S. GAAP for complete financial statement presentation. These unaudited interim condensed financial statements should be read in conjunction with audited financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. In the opinion of management, the interim condensed financial statements include all normal, recurring adjustments which are considered necessary for a fair presentation of the financial position of the Company at March 31, 2023, and the results of operations and cash flows for the three month periods ended March 31, 2023 (the “First Quarter 2023”) and March 31, 2022 (the “First Quarter 2022”).

Operating results for the First Quarter 2023 are not indicative of results that will be reported for the year ending December 31, 2023 as the Company sold substantially all of its assets on February 28, 2023 to Healgen Scientific, LLC (“Healgen”). Amounts at December 31, 2022 are derived from audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

During the First Quarter 2023, there were no significant changes to the Company’s critical accounting policies, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

The preparation of these interim condensed financial statements requires the Company to make estimates and judgments that affect the reported amounts of liabilities, expenses, and related disclosure of contingent liabilities. On an on-going basis, the Company evaluates estimates, including those related to bad debts, income taxes, warranty obligations, contingencies and litigation. The Company bases estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

These unaudited interim condensed financial statements have been prepared assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty. The independent registered public accounting firm’s report on the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, contained an explanatory paragraph regarding the Company’s ability to continue as a going concern. As of the date of this report, the Company’s current cash balances and amounts expected from its receivables (including the Employee retention Credit receivable and the retention (escrow) proceeds from the asset sale) may not be sufficient to fund the Company through May 2024.

The Company’s credit facilities with Cherokee Financial, LLC (“Cherokee”) were paid in full with proceeds from the asset sale on February 28, 2023.

Recently Adopted Accounting Standards

ASU 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations, issued in September 2022, requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about obligations outstanding at the end of the reporting period, including a rollforward of those obligations. The guidance does not affect the recognition, measurement or financial statement presentation of supplier finance program obligations. ASU 2022-04 became effective on January 1, 2023. The Company adopted ASU 2022-04 on January 1, 2023 and the adoption did not have an impact on the Company’s financial condition or results of operations as the Company does not (and has not historically) utilized supplier finance programs in connection with the purchase of goods and services.

Table of Contents

ASU 2016-13, Financial Instruments—Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, issued in June 2016, requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted ASU 2016-13 on January 1, 2023 and the adoption did not have a material impact on the Company’s financial condition or results of operations.

Accounting Standards Issued; Not Yet Adopted

ASU 2022-03, Fair Value Measurement (Topic 820), Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, issued in June 2022, clarifies that a contractual restriction on the sale of an equity security is not considered in measuring the security's fair value. The standard also requires certain disclosures for equity securities that are subject to contractual restrictions. ASU 2022-03 becomes effective on January 1, 2024. Early adoption is permitted. The Company is evaluating the impact of ASU 2022-03.

Any other new accounting pronouncements recently issued, but not yet effective, have been reviewed and determined to be not applicable or were related to technical amendments or codification. As a result, the adoption of such new accounting pronouncements, when effective, is not expected to have a material effect on the Company’s financial position or results of operations.

Note B – Inventory

Inventory is comprised of the following:

	March 31, 2023*		December 31, 2022

Raw Materials	$	0	$	444,000
Work In Process		0		110,000
Finished Goods		0		60,000
Allowance for slow moving and obsolete inventory		0		(235,000	)
	$	0	$	379,000

*On February 28, 2023, the Company sold substantially all of its assets to Healgen, including its inventory.

Note C – Property, Plant and Equipment

Property, plant and equipment, is comprised of the following:

	March 31, 2023*		December 31, 2022

Land	$	0	$	102,000
Buildings and improvements		0		1,352,000
Manufacturing and warehouse equipment		0		2,110,000
Office equipment (incl. furniture and fixtures)		0		412,000
		0		3,976,000
Less accumulated depreciation		0		(3,510,000	)
	$	0	$	466,000

*On February 28, 2023, the Company sold substantially all of its assets to Healgen, including its property, plant and equipment.

Table of Contents

Note D – Accrued Expenses

Accrued expenses and other current liabilities consisted of the following as of March 31, 2023 and December 31, 2022:

	March 31, 2023		December 31, 2022
Accounting fees	$	16,000	$	87,000
Interest payable		20,000		39,000
Accounts receivable credit balances		0		1,000
Sales tax payable		188,000		188,000
Deferred compensation		114,000		109,000
Other current liabilities		0		90,000
	$	338,000	$	514,000

Note E – Net Income / (Loss) Per Common Share

Basic net income / (loss) per common share is calculated by dividing the net income / (loss) by the weighted average number of outstanding common shares during the period. Diluted net income / (loss) per common share includes the weighted average dilutive effect of stock options and warrants. When the Company has a loss, option and warrants are not included as they would be anti-dilutive. In the three months ended March 31, 2023, although the Company had net income, there were no options in the money at March 31, 2023. Potential common shares outstanding as of March 31, 2023 and 2022:

	March 31, 2023		March 31, 2022
Options		1,690,000		1,937,000
Total		1,690,000		1,937,000

Note F – Litigation/Legal Matters

From time to time, the Company may be involved in immaterial legal proceedings in connection with matters that arise during the normal course of business. While the ultimate outcome of any such immaterial litigation cannot be predicted, if the Company is unsuccessful in defending any such litigation, the resulting financial losses are not expected to have a material adverse effect on the financial position, results of operations or cash flows of the Company.

Note G – Debt

The Company’s Line of Credit and Debt consisted of the following as of March 31, 2023 and December 31, 2022:

	March 31, 2023		December 31, 2022
Loan and Security Agreement with Cherokee Financial, LLC: Secured note executed on February 15, 2015, at a fixed annual interest rate of 8% plus a 1% annual oversight fee, interest and oversight fee paid quarterly with principal due on February 15, 2020. Loan was extended for one year (until February 15, 2021) under the same terms and conditions as the original loan. The loan was further extended in February 2021 to February 15, 2022 with $100,000 added to the loan principal as a penalty and the annual interest rate increased to 10%. Loan was further extended in June 2022 (until February 15, 2023). Loan was paid in full on February 28, 2023.	$	0	$	1,000,000
2019 Term Loan with Cherokee Financial, LLC: Note at an annual fixed interest rate of 18% paid quarterly in arrears and a balloon payment due on February 15, 2020. Loan was extended in February 2020, until February 15, 2021 with a penalty of $20,000 added to the loan principal and, extended again in February 2021 to February 15, 2022 with another penalty of $20,000 added to the loan principal. Loan was extended in June 2022 (until February 15, 2023). Loan was paid in full on February 28, 2023.		0		240,000
November 2020 Shareholder Note: Term loan at 7% interest with the first interest only payment being made on February 4, 2021 and the final interest and $50,000 principal due on November 4, 2023.		50,000		50,000
December 2021 Shareholder Notes: Term loan with one non-affiliated shareholder at 7% interest until the loan is paid in full. Loan was amended to address additional amounts provided under the loan.		125,000		225,000
September 2022 Healgen Loan & Promissory Note: Term Loan with Healgen at a fixed rate of 1% per month compounded monthly. Loan was collateralized by first security interest in receivables, inventory, and all other assets with the exception of assets already encumbered. The Healgen loan was paid in full on February 28, 2023 (the closing of the Asset Sale to Healgen) and all interest was waived by Healgen.		0		715,000
Total Debt	$	175,000	$	2,230,000
Current portion	$	175,000	$	2,230,000

Table of Contents

LOAN AND SECURITY AGREEMENT (“LSA”) WITH CHEROKEE FINANCIAL, LLC (“CHEROKEE”)

On March 26, 2015, the Company entered into a LSA with Cherokee (the “Cherokee LSA”) in the amount of $1,200,000, which was collateralized by a first security interest in real estate and machinery and equipment. The Cherokee LSA reached maturity on February 15, 2020 with a balance of $900,000 (after 4 principal reduction payments of $75,000 each were made over the course of the initial term). In February 2020, the Cherokee LSA was extended for one year, or until February 15, 2021. No terms of the facility were changed under the February 2020 extension.

In February 2021, the Cherokee LSA was further extended for another year, or until February 15, 2022 (the “February 2021 Extension”). Under the February 2021 Extension, the principal of the Cherokee LSA was increased to $1,000,000 to include a $100,000 penalty that was due as a result of the Company being unable to pay back the principal balance to Cherokee on February 15, 2021. The annual interest rate on the Cherokee LSA was also increased to a fixed rate of 10% (the prior fixed rate was 8%) plus a 1% annual oversight fee (that remained unchanged). Interest and the oversight fee were still due quarterly.

Under the terms of the February 2021 Extension, if the Company didn’t pay off the principal on or before February 15, 2022, Cherokee could charge an 8% delinquent fee on the principal balance ($1,000,000) on February 15, 2022. The Company was not able to pay off the facility on February 15, 2022; however, on June 14, 2022 Cherokee agreed that they would defer the principal amounts due under the Cherokee LSA until February 15, 2023 and that any applicable penalties would also be deferred as long as the Company remained current on the quarterly interest payments.

On February 28, 2023, with proceeds from the Asset Sale to Healgen, the Company paid all amounts due to Cherokee under the LSA for principal and interest.

The Company recognized $13,000 in interest expense related to the Cherokee LSA in the First Quarter 2023 and $25,000 in interest expense related to the Cherokee LSA in the First Quarter 2022

As of March 31, 2023 and December 31, 2022, the balance of the Cherokee LSA was $0 and $1,000,000, respectively.

Table of Contents

2019 TERM LOAN WITH CHEROKEE

In February 2019, the Company entered into an agreement with Cherokee under which Cherokee provided the Company with a loan in the amount of $200,000 (the “2019 Cherokee Term Loan”). The annual interest rate under the 2019 Cherokee Term Loan was 18% (fixed) paid quarterly in arrears.

In February 2020, the 2019 Cherokee Term Loan was extended for one year, or until February 15, 2021. No terms of the facility were changed under the February 2020 extension. The Company incurred a penalty in the amount of $20,000 which was added to the principal balance of the 2019 Cherokee Term Loan; bringing the principal to $220,000.

In February 2021, the 2019 Cherokee Term Loan was further extended to February 15, 2022. Under the terms of this additional extension, the 2019 Cherokee Term Loan was increased to $240,000 to include a $20,000 penalty that was due as a result of the Company being unable to pay back the principal balance to Cherokee on February 15, 2021. In addition, if the Company didn’t pay off the principal on or before February 15, 2022, Cherokee could charge an 8% delinquent fee on the principal balance ($240,000) on February 15, 2022. The Company was not able to pay off the facility on February 15, 2022; however, on June 14, 2022 Cherokee agreed that they would defer the principal amounts due under the 2019 Cherokee Term Loan until February 15, 2023 and that any applicable penalties would also be deferred as long as the Company remained current on the quarterly interest payments.

The Company recognized $4,000 in interest expense in the First Quarter 2023 and $11,000 in interest expense in the First Quarter 2022. The Company paid all principal and interest due to Cherokee on February 28, 2023 with proceeds from the Asset Sale to Healgen. The balance of the 2019 Cherokee Term Loan was $0 at March 31, 2023 and $240,000 at December 31, 2022.

NOVEMBER 2020 TERM LOAN

On November 4, 2020, the Company entered into a loan agreement with an individual shareholder in the principal amount of $50,000. There were no expenses related to the term loan and the interest rate is 7%. The first interest only payment was made on February 4, 2021 and the final interest payment and principal was due on May 4, 2021. On May 4, 2021, the Company extended this loan for another 6 months, or until November 4, 2021. The interest rate and all other terms of the note remained unchanged under this extension.

On November 4, 2021, the November 2020 Term Loan was extended again. Under this extension, the principal was due on November 4, 2022. The last interest payment made to the shareholder was in November 2021 and was for the period of August 5, 2021 through November 4, 2021. The shareholder agreed to defer the quarterly interest payments due on the extended facility. The facility was further extended on November 4, 2022, under the same terms and conditions, for another 6 months, or until May 4, 2023.

The Company recognized less than $1,000 in interest expense related to the November 2020 Term Loan in the First Quarter 2023 and $1,000 in interest expense in the First Quarter 2022. The balance on the November 2020 Term Loan was $50,000 at March 31, 2023 and December 31, 2022. (See Note M – Subsequent Events for more information on the November 2020 Term Loan)

DECEMBER 2021 SHAREHOLDER LOANS

On December 14, 2021, the Company entered into Loan Agreements with two non-affiliated shareholders resulting in gross (and net) proceeds of $75,000 as there were no costs associated with the loans. Interest on the loans was 7% per annum until principal and interest were due in full, or until June 15, 2022. The first interest payments were due March 15, 2022 and payment of final interest and principal was due June 15, 2022.

One of the loans (in the amount of $25,000) was paid in full on June 13, 2022 along with the final interest payment due.

On April 6, 2022, the Company amended the loan with the other non-affiliated shareholder. This amendment (No.1; hereinafter referred to in this paragraph as “Amendment No. 1”) increased the principal due to the shareholder by $25,000; bringing their total principal to $75,000. No other terms of the loan were changed under Amendment No. 1.

Table of Contents

On April 14, 2022, the loan was amended again (under Amendment No. 2; hereinafter referred to in this paragraph as “Amendment No. 2”) increasing the principal again by $50,000; bringing their total principal to $125,000. No other terms of the loan were changed under Amendment No. 2.

On May 11, 2022, the loan was amended again (under Amendment No. 3; hereinafter referred to in this paragraph as “Amendment No. 3”) increasing the principal again by $75,000; bringing their total principal to $200,000. The loan was further amended to include a specific payment schedule based on receipt of anticipated ERC refunds.

On June 13, 2022, the Company made a principal reduction payment to this shareholder in the amount of $25,000 from proceeds from the ERC refund received on June 2, 2022; bringing the principal amount owed on the loan to $175,000.

On July 13, 2022, the loan was amended again (under Amendment No. 4; hereinafter referred to in this paragraph as “Amendment No. 4”) increasing the principal by $25,000; bringing their total principal to $200,000 again. The loan agreement was also amended to revise the maturity date from June 15, 2022 to no specific maturity date.

On September 13, 2022, the loan was amended again (under Amendment No. 5; hereinafter referred to in this paragraph as “Amendment No. 5”) increasing the principal by $25,000; bringing their total principal to $225,000 again.

On September 28, 2022, the shareholder provided the Company with additional funds, $40,000, under this loan with the understanding that the amount would be paid back once the Healgen Loan funds were received and there would be no interest charged on this additional amount. This increased the amount due to the shareholder under the facility to $265,000. The Company did pay this additional amount in full on October 4, 2022; bringing the balance of the loan back to $225,000.

The Company incurred $4,000 in interest expense related to these loans in the First Quarter 2023 and $1,000 in interest expense related to these loans in the First Quarter 2022.

The balance on these loans was $125,000 on March 31, 2023 and $225,000 at December 31, 2022. (See Note M – Subsequent Events for more information on the December 2021 Shareholder Loans)

SEPTEMBER 2022 HEALGEN LOAN & PROMISSORY NOTE

On September 28, 2022, the Company entered into a Loan and Promissory with Healgen Scientific Limited Liability Company (the “Healgen Loan”) at a fixed rate of 1% per month, (compounded monthly) and received initial gross/net proceeds of $40,000 and subsequent gross/net proceeds of $360,000; for a total of $400,000. The Company utilized $34,000 of the loan proceeds to pay off the Crestmark Line of Credit and the balance was used for working capital. The Healgen Loan was collateralized by a first security interest in the Company’s receivables, inventory, and all other assets with the exception of those assets already encumbered. The first payment under the Healgen Loan was due on January 28, 2023 and was in the amount of $140,000.

The Healgen Loan was amended on November 15, 2022 to increase the principal due under the loan to $700,000. Under this first amendment, the loan maturity date was extended to April 15, 2023 and the first payment date was extended to February 15, 2023 and changed to $246,000.

The Healgen loan was amended again on December 19, 2022 to increase the principal due under the loan to $715,000. Under this second amendment, the amount of the first payment was changed to $251,000 with payments of the same amount due on March 15, 2023 and April 15, 2023.

The Healgen Loan was amended again on January 6, 2023 to increase the principal due under the loan to $815,000. Under this third amendment, the amount of the first payment (due February 15, 2023) was changed to $286,000 with payments of the same amount due on March 15, 2023 and April 15, 2023. No other terms of the Healgen Loan were changed.

The Healgen Loan was amended again on February 9, 2023 to increase the principal due under the loan to $965,000. Under this fourth amendment, the amount of the first payment (due February 15, 2023) was changed to $337,000 with payments of the same amount due on March 15, 2023 and April 15, 2023. No other terms of the Healgen Loan were changed.

Table of Contents

On February 28, 2023, with proceeds from the Asset Sale to Healgen, the Company made a payment in the amount of $965,000 to Healgen for all principal due under the Healgen Loan. Healgen waived all interest due under the Healgen Loan.

The balance on the Healgen Loan was $0 at March 31, 2023 and $715,000 at December 31, 2022.

OTHER DEBT INFORMATION

In addition to the debt indicated previously, previous debt facilities (paid in full via refinance or conversion into equity) had financial impact on the First Quarter 2022. More specifically:

LINE OF CREDIT WITH CRESTMARK BANK (“CRESTMARK”)

On June 29, 2015, the Company entered into a Loan and Security Agreement (“LSA”) with Crestmark related to a revolving line of credit (the “Crestmark LOC”). The Crestmark LOC was used for working capital and general corporate purposes. Upon completion of the initial 5 year term, the Crestmark LOC automatically renewed for additional one (1) year terms unless notice of termination from the Company was received by Crestmark not less than sixty (60) days prior to the end of the renewal term. On September 29, 2022, the Company made a payment to Crestmark in the amount of $34,000 which paid off the balance on the Crestmark LOC.

The Company incurred $0 in interest expense in the First Quarter 2023 and $10,000 in interest expense in the First Quarter 2022.

NOTE H – Employee Retention Credit

The employee retention credit (“ERC”), as originally enacted on March 27, 2020 by the CARES Act, was a refundable tax credit against certain employment taxes equal to 50% of the qualified wages an eligible employer paid to employees and allowed claims through December 31, 2021 by eligible employers who retained employees during the Covid-19 pandemic. However, in November 2021, the ERC was terminated as of September 30, 2021 instead of December 31, 2021.

The maximum qualified wages for each employee under the ERC was $10,000 per quarter. Also, because the Company has 100 or fewer full-time employees, health plan expenses borne by the Company could also be included as qualified wages in addition to salary. In August 2021, the Company’s payroll service provider processed and mailed a Form 941-X to claim a refund in the amount of $202,000 on qualified wages paid in the first quarter of 2021. Due to a change in the Form 941-X, the Company’s payroll service provider did not process and mail its Form 941-X to claim a refund in the amount of $198,000 on qualified wages paid in the second quarter of 2021 until October 28, 2021.

The Company was informed that the IRS did not have record of receiving the Company’s Form 941-X for the first quarter of 2021 (which was mailed by the Company’s service provider in August 2021). The Company re-sent the Form 941-X for the first quarter of 2021 via overnight service on December 31, 2021 and the IRS received it on January 5, 2022. This lack of receipt resulted in a delay in receiving the expected refund in the amount of $202,000.

On June 2, 2022, the Company received a refund for the second quarter of 2021 in the amount of $199,000. This amount represents the $198,000 claimed as a refund and $1,000 in interest. The Company has had a number of discussions with the IRS and has been given a number of time frames in which the refund for the first quarter of 2021 could be expected. As of March 31, 2023, the Company had not yet received the refund. (See Note M – Subsequent Events for updated information on the ERC refund)

Note I – Asset Sale to Healgen

Over the last several years, the Company has retained financial consultants to seek out alternative solutions; most recently in early Fiscal 2022. The consultants were seeking solutions including but not limited to potential mergers, acquisitions, investment in the Company, and strategic relationships. Simultaneously, the Company’s management was seeking alternative solutions and began discussions with Healgen. With the current financial condition of the Company, the Company was not able to find a suitable alternative apart from the Asset Sale to Healgen.

After carefully weighing the facts and circumstances associated with the Asset Sale to Healgen as well as alternative courses of action, the Company’s Board of Directors (the “Board”) unanimously concluded that the proposed sale of substantially all of the Company’s assets was the best available alternative to maximize value for shareholders.

Table of Contents

The Board believes the Company’s status as a fully reporting public company is an asset which may be sufficiently attractive to induce others to enter into business combinations with the Company. The Company is exploring strategic transactions which may result in entering into a new line of business (subject to specific competitive limitations under the Asset Sale to Healgen). The Company believes strategic acquisitions using the Company’s publicly traded stock as transaction consideration could enhance shareholder value. Nonetheless, the Board may later determine to dissolve the Company and distribute any remaining assets to the Company’s shareholders if the Company is unable to make any strategic acquisitions or enter into any strategic transactions.

On December 19, 2022, the Company entered into an Asset Purchase Agreement (“APA”) with Healgen, pursuant to which the Company agreed, subject to the approval of its shareholders, to sell substantially all of the Company’s operating assets (excluding its cash, accounts receivables arising prior to the closing date, and certain other assets). The Company submitted the Asset Sale to Healgen to a shareholder vote via a preliminary Proxy Statement filed on December 22, 2022. On January 5, 2023, the Company filed an amendment to its Preliminary Proxy Statement and on January 11, 2023, the Company filed its Definitive Proxy Statement with the SEC.

On February 15, 2023, the Company held the 2023 Special Meeting of Shareholders (the “Special Meeting”) at the Company’s corporate offices in Kinderhook, New York, at which a quorum (27,863,899 shares of common stock of the 47,098,476 shares of common stock outstanding) was present in person or represented by proxy.

Approval of the Asset Sale to Healgen required the affirmative vote of the holders of a majority of the outstanding shares of the Company’s common stock (par value $0.01). 26,381,832, or 54.84% of the total outstanding shares of the Company, voted in favor of the Asset Sale to Healgen. 1,476,077, or 3.06% of the total outstanding shares, voted against the Asset Sale to Healgen. 5,990, or 0.01% of the total shares outstanding, withheld voting on the Asset Sale to Healgen. Given the majority of total outstanding shares voted in favor of the Asset Sale to Healgen, the Asset Sale to Healgen was approved.

On February 28, 2023, the Company completed the Asset Sale to Healgen and disposition of substantially all of the Company’s assets. In connection with the closing of the Asset Sale to Healgen, and in accordance with the terms of the Asset Purchase Agreement, Healgen paid an aggregate purchase price of $3 million (“Purchase Price”). $300,000 of the Purchase Price is being held back in a retention fund to cover potential indemnification claims during the six months following the close. Net proceeds in the amount of $247,000 were received by the Company after satisfaction of 1) a loan with Healgen in the amount of $965,000, 2) the Cherokee LSA, (totaling $1,031,000 for principal and interest through February 27, 2023), 3) the 2019 Cherokee Term Loan (totaling $252,000 for principal and interest through February 27, 2023), 4) delinquent property related taxes in the amount of $193,000 and 5) $12,000 for current property related taxes.

NOTE J – Stock Options and Warrants

The Company has two non-statutory stock option plans, the Fiscal 2001 Non-statutory Stock Option Plan (the “2001 Plan”) and the 2013 Equity Compensation Plan (the “2013 Plan”). Both plans have been adopted by the Board of Directors and approved by shareholders. Both the 2001 Plan and the 2013 Plan have options available for future issuance. Any common shares issued as a result of the exercise of stock options would be new common shares issued from our authorized issued shares.

During the First Quarter 2023 and the First Quarter 2022, the Company issued 0 options to purchase shares of common stock.

Stock option activity for the First Quarter 2023 and the First Quarter 2022 is summarized as follows (the figures contained within the tables below have been rounded to the nearest thousand):

Table of Contents

	First Quarter 2023						First Quarter 2022
	Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value as of March 31, 2023		Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value as of March 31, 2022
Options outstanding at beginning of year		1,736,000	$	0.12				1,937,000	$	0.13
Granted		0	NA					0	NA
Exercised		0	NA					0	NA
Cancelled/expired		46,000	$	0.26				0	NA
Options outstanding at end of quarter		1,690,000	$	0.12	$	0		1,937,000	$	0.13	$	0
Options exercisable at end of quarter		1,690,000	$	0.12				1,937,000	$	0.13

The Company recognized $0 in share based payment expense in the First Quarter 2023 and the First Quarter 2022. At March 31, 2023, there was $0 of unrecognized share based payment expense related to stock options.

NOTE K – Changes in Stockholders’ Deficit

LANDMARK CONSULTING AGREEMENT

On March 7, 2022, the Company entered into a Financial Advisory Agreement (the “Agreement”) with Landmark Pegasus, Inc. (‘Landmark”). The Agreement provided that Landmark would provide certain financial advisory services for a minimum period of 3 months (which period commenced on February 28, 2022), and as consideration for these services, the Company would pay Landmark (a) a retainer fee consisting of 500,000 restricted shares of common stock and a warrant to purchase 2.75 million shares of the Company’s common stock at a strike price equal to the average closing price of the Company’s common shares for the 30 days preceding the Agreement, or $0.035 per share, resulting in gross proceeds to the Company in the amount of $96,250. The warrant would vest upon the closing of a transaction involving Landmark or upon the invocation of a “Breakup Fee”.

In a subsequent amendment, the terms of the warrant were changed to reflect that the warrant would be issued immediately preceding the closing of a transaction involving Landmark or immediately upon the invocation of the Breakup Fee. In each case, the warrant would vest immediately (i.e. the warrant would be 100% immediately exercisable).

The Breakup Fee would be invoked upon the generation of a specific transaction to ABMC which meets certain criteria agreed upon by both the Company and Landmark; which transaction is then rejected by the Company. The Company would also pay to Landmark a “Success Fee” for the consummation of a transaction closing during the term of the Agreement and for 12 months thereafter, between the Company and any party first introduced to the Company by Landmark, or with any party the Company has specifically requested Landmark’s assistance with the transaction. Upon invocation of the Breakup Fee or payment of the Success Fee, the Company would also issue an additional 250,000 restricted shares of the Company’s common stock. In the event that the Company consummated a transaction involving the provision of services to any party introduced to the Company by Landmark or with any party the Company has specifically requested Landmark’s assistance with, the Company would pay Landmark 10% of any revenues received from the transaction, unless this percentage is modified by both the Company and Landmark in writing. There is no material relationship between the Company and Landmark, other than with respect to the Agreement.

Apart from the initial 500,000 restricted common shares, no additional stock was issued to Landmark and no further amounts were paid to Landmark.

Note L- Income Taxes

The Company follows ASC 740 “Income Taxes” (“ASC 740”) which prescribes the asset and liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted laws and tax rates that will be in effect when the differences are expected to reverse. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits that are not expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. Under ASC 740, tax benefits are recorded only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon ultimate settlement. Unrecognized tax benefits are tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. With regards to the use of net losses incurred for 2018 and later, such net operating losses have no expiration, while taxable income can only be offset up to 80% of taxable income. Net operating losses incurred prior to 2018 may be fully utilized to offset taxable income.

Table of Contents

A reconciliation of the U.S. Federal statutory income tax rate to the effective income tax rate is as follows:

	Quarter Ended March 31, 2023			Quarter Ended March 31, 2022
Tax expense at federal statutory rate	(21%)			(21%)
State tax expense, net of federal tax effect		0	%		0	%
Increase in valuation allowance		21	%		21	%
Effective income tax rate	(0%)			(0%)

Significant components of the Company’s deferred income tax assets are as follows:

	March 31, 2023			December 31, 2022
					13,
Inventory allowance	$	0		$	61,000
Allowance for doubtful accounts		1,000			1,000
Stock based compensation		138,000			149,000
Deferred wages payable		30,000			21,000
Depreciation – Property, Plant & Equipment		0			(19,000	)
Research and development credits		26,000			24,000
Net operating loss carry-forward		2,482,000			2,972,000
Total gross deferred income tax assets		2,677,000			3,209,000
Less deferred income tax assets valuation allowance		(2,677,000	)		(3,209,000	)
Net deferred income tax assets	$	0			0

The valuation allowance for net deferred income tax assets as of March 31, 2023 and December 31, 2022 was $2,677,000 and $3,209,000, respectively. The net change in the valuation allowance was $532,000 at March 31, 2023 and $91,000 at March 31, 2022. The Company believes that it is more likely than not that the net deferred tax assets will not be realized.

As of March 31, 2023, the prior three years remain open for examination by the federal or state regulatory agencies for purposes of an audit for tax purposes.

At March 31, 2023, the Company had Federal net operating loss carry-forwards for income tax purposes of approximately $11,427,000 and research and development credits of $26,000. The Company’s net operating loss carry-forwards began to expire in 2022 and continue to expire through 2038. Net operating losses incurred from 2018 to date have no expiration. In assessing the reliability of deferred income tax assets, management considers whether or not it is more likely than not that some portion or all deferred income tax assets will be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the projected future taxable income and tax planning strategies in making this assessment.

The Company’s ability to utilize the operating loss carry-forwards and research and development credits may be subject to an annual limitation in future periods pursuant to Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, if future changes in ownership occur.

The Company recognizes potential interest and penalties related to income tax positions as a component of the provision for income taxes on operations. The Company does not anticipate that total unrecognized tax benefits will materially change in the next twelve months.

Table of Contents

Note M – Subsequent Events

ERC Refund

The Company has been expecting an ERC refund in the amount of $202,000. On April 17, 2023, the Company received payments in the amount of $156,000 and $2,000 from the IRS. There was not any communication with either of the payments. As of the date of this report, the Company is making efforts to speak with the IRS to determine the reason behind the lower refund being received and to determine if additional payments can be expected.

November 2020 Term Loan

Upon receipt of the payment from the IRS, the Company paid the principal balance due ($50,000) on this shareholder loan.

December 2021 Shareholder Loan

Upon receipt of the payment from the IRS, the Company made a payment in the amount of $25,000 on this shareholder loan. As of the date of this report, the balance on the December 2021 Shareholder Loan is $175,000.

Current Salary owed to Melissa Waterhouse

Upon receipt of the payment from the IRS, the Company made a payment in the amount of $32,000 to Melissa Waterhouse to pay current salary owed. As of the date of this report, the amount due to Melissa Waterhouse for deferred compensation is $92,000. Ms. Waterhouse is also owed $12,000 for consulting services from March 2023 through May 2023.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

General

The following discussion and analysis provides information, which we believe is relevant to an assessment and understanding of our financial condition and results of operations. The discussion should be read in conjunction with the Interim Condensed Financial Statements contained herein and the notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q. Certain statements contained in this Quarterly Report on Form 10-Q, including, without limitation, statements containing the words “believes”, “anticipates”, “estimates”, “expects”, “intends”, “projects”, and words of similar import, are forward-looking as that term is defined by the Private Securities Litigation Reform Act of 1995 (“1995 Act”), and in releases issued by the United State Securities and Exchange Commission (the “Commission”). These statements are being made pursuant to the provisions of the 1995 Act and with the intention of obtaining the benefits of the “Safe Harbor” provisions of the 1995 Act. We caution that any forward-looking statements made herein are not guarantees of future performance and that actual results may differ materially from those in such forward-looking statements as a result of various factors, including, but not limited to, any risks detailed herein, in our “Risk Factors” section of our Form 10-K for the year ended December 31, 2022, in our most recent reports on Form 10-Q and Form 8-K and from time to time in our other filings with the Commission, and any amendments thereto. Any forward-looking statement speaks only as of the date on which such statement is made, and we are not undertaking any obligation to publicly update any forward-looking statements. Readers should not place undue reliance on these forward-looking statements.

Overview

Throughout the last several years, our products sales have been negatively impacted as customer pricing continues to decrease as a result of our markets being saturated with products made outside of the United States; primarily products made in China. This has resulted in a commoditization of the onsite drug testing market at a time when costs associated with labor, utilities, materials, insurance, etc. keep rising. In attempts to retain current customers and/or attract new customers that require lower pricing, we have been offering customers two drug test product lines that are manufactured in China.

Other efforts to offset declines in our manufactured product sales involved selling various diagnostic product lines, including but not limited to, various Covid-19 rapid tests. In addition to increased costs, materials used in the manufacture of our drug test products are the same materials used in the manufacture of lateral flow Covid-19 tests as well as lateral flow tests for Influenza and RSV, both of which surged in the latter part of Fiscal 2022. This increased need for the same materials has resulted in supply chain delays; some of which negatively impacted our customer relationships. One of those customers was our largest customer which severely negatively impacted our sales.

Table of Contents

Gross margin has continually declined over the last several years due to the increased costs of manufacturing in the United States and the fact that overhead costs associated with both of our facilities could not be decreased any further. As sales continued to decline, these costs cannot be adjusted downward, thereby creating greater manufacturing inefficiencies. Manufacturing inefficiencies continued to increase despite our efforts to mitigate them. Efforts were also made to control operational expenses to ensure they remained in line with sales, however, as a reporting public company; there is a certain level of expenses that much be maintained.

From August 2013 until June 2020 we maintained a salary deferral program for our sole executive officer, our Chief Executive Officer/Principal Financial Officer Melissa Waterhouse. The salary deferral program was initiated by Ms. Waterhouse voluntarily in both August 2013 and April 2022. In the First Quarter of 2022, we did make payments to Ms. Waterhouse totaling $10,000. We stopped making payments on Ms. Waterhouse’s deferred compensation in April 2022 when Ms. Waterhouse again voluntarily deferred her salary by 20%. This deferral remained in place through February 28, 2023.

As of March 31, 2023, we had deferred compensation owed to Ms. Waterhouse in the amount of $92,000 and $7,000 in payroll taxes that are due as payments are made to Ms. Waterhouse; for a total of $99,000 in deferred compensation owed to Ms. Waterhouse. In addition, as of March 31, 2023, we owed Ms. Waterhouse $32,000 in current salary that was not paid. (See Note M – Subsequent Events for updated information on the currently salary owed to Ms. Waterhouse)

Beginning in April 2022, another member of senior management participated in the salary deferral program. As of March 31, 2023, we had deferred compensation owed to this individual in the amount of $14,000 and $1,000 in payroll taxes that are due as payments are made to this individual; for a total of $15,000 in deferred compensation. This individual ceased participating in the salary deferral program on December 9, 2022 and received their full salary through February 28, 2023 (the closing date of the Asset Sale to Healgen).

Asset Sale to Healgen/Outlook

On February 28, 2023, we completed the Asset Sale to Healgen and disposition of substantially all of the Company’s assets. In connection with the closing of the Asset Sale to Healgen, and in accordance with the terms of the Asset Purchase Agreement, Healgen paid an aggregate purchase price of $3 million (“Purchase Price”). $300,000 of the Purchase Price is being held back in a retention fund to cover potential indemnification claims during the six months following the close. Net proceeds in the amount of $247,000 were received by the Company after satisfaction of 1) a loan with the Healgen in the amount of $965,000, 2) the Cherokee LSA, (totaling $1,031,000 for principal and interest through February 27, 2023), 3) the 2019 Cherokee Term Loan (totaling $252,000 for principal and interest through February 27, 2023), 4) delinquent property related taxes in the amount of $193,000 and 5) $12,000 for current property related taxes.

The Board believes our status as a fully reporting public company is an asset which may be sufficiently attractive to induce others to enter into business combinations. The Board is exploring strategic transactions which may result in entering into a new line of business (subject to specific competitive limitations under the Asset Sale to Healgen). The Board believes strategic acquisitions using the Company’s publicly traded stock as transaction consideration could enhance shareholder value. Nonetheless, the Board may later determine to dissolve the Company and distribute any remaining assets to the Company’s shareholders if the Company is unable to make any strategic acquisitions or enter into any strategic transactions.

Results of operations for the First Quarter 2023 compared to the First Quarter 2022

NET SALES:Net sales for the First Quarter 2023 decreased 53.3% when compared to net sales in the First Quarter 2022 primarily as a result in a decline in sales of drugs of abuse (“DOA”) test that we manufacture and the fact that our last product sale was recorded on February 28, 2023. The decline in DOA sales stems almost entirely from decreased sales to our largest customer who has historically been a significant portion of our revenues. This customer had two segments of their business for which we supplied products. They informed us in February 2022 that sales to one of those segments (which we supplied exclusively) would decrease as a result of their desire to have multiple vendors supplying the segment. They indicated this was to ensure uninterrupted supply as they had experienced periodic supply interruptions with us in 2021 (as a result of the supply chain issues we experienced in 2021 and continued to experience into 2022).

Table of Contents

GROSS PROFIT:Gross profit increased to 45.1% of net sales in the First Quarter 2023 from 8% of net sales in the First Quarter 2022. This increase in gross profit stems from the timing of the closing of the Asset Sale to Healgen and the fact that the bulk of the sales in the First Quarter 2023 were higher margin sales of the private labeled RSV product we supplied to an unaffiliated third party.

OPERATING EXPENSES: Operating expenses decreased in the First Quarter 2023 compared to the First Quarter 2022. Selling and Marketing and General and Administrative expenses decreased while Research and Development expenses increased. More specifically:

Research and development (“R&D”)

R&D expense increased 27.3%, when comparing the First Quarter 2023 with the First Quarter 2022. FDA compliance costs (the cost of facility registrations and their timing) were the primary cause of the increase. The increase was partially offset by decreased salary expense since payroll ceased on February 28, 2023; closing of the Asset Sale to Healgen.

Selling and marketing

Selling and marketing expense in the First Quarter 2023 decreased 52.4% when compared to the First Quarter 2022. Reductions in sales salary expense and benefits (due to the closing of the Asset Sale to Healgen on February 28, 2023) offset by increased costs associated with shipping were the primary reason for the decline in expenses.

General and administrative (“G&A”)

G&A expense decreased 19.3% in the First Quarter 2023 compared to the First Quarter 2022. G&A salary expense and benefits (related to purchasing, warehouse, quality assurance and administrative personnel) decreased as a result of the closing of the Asset Sale to Healgen on February 28, 2023. Consulting fees also decreased when comparing the two periods. These declines were partially offset by increased costs associated with the Asset Sale to Healgen (legal fees, taxes, and insurance). There was no expense related to share based payments in either the First Quarter 2023 or the First Quarter 2022.

Other income / (expense):

Other income in the First Quarter 2023 consisted of other income of $3,035,000 (which is the $3,000,000 purchase price paid for the Company’s assets and $35,000 in amounts reimbursed by Healgen in connection with the Asset Sale; pro-rated real estate taxes and payment of 50% of the payout related to employee vacation expense). This income was offset by a loss on the sale of assets ($921,000) and interest expense associated with our debt.

Other expense in the First Quarter 2022 consisted of interest expense associated with our credit facilities (our (now former) line of credit with Crestmark Bank, our loans with Cherokee Financial, LLC and our loans with two shareholders).

Liquidity and Capital Resources as of March 31, 2023

Until the closing of the Asset Sale to Healgen on February 28, 2023, our cash requirements depend on numerous factors, including but not limited to manufacturing costs (such as labor and overhead costs, raw materials, equipment, etc.), selling and marketing initiatives, product development activities, regulatory costs, legal costs, and effective management of inventory levels and production levels in response to sales history and forecasts (if available). Since the closing of the Asset Sale to Healgen, our cash requirements depend on the costs we will need to incur to maintain our status as a fully reporting public entity and the time it will take to either bring another business into the public shell or dissolve the Company and distribute any remaining assets to the shareholders; along with management of amounts due to vendors and receipt of additional customer receivables and receipt of the retention fund.

The following transactions materially impacted our liquidity and cash flow in the First Quarter 2023 and/or the First Quarter 2022 or are expected to have an impact on our cash flow in the year ending December 31, 2023:

Asset Sale to Healgen

Table of Contents

On December 19, 2022, we entered into an Asset Purchase Agreement (“APA”) with Healgen, pursuant to which the Company agreed, subject to the approval of its shareholders, to sell substantially all of our operating assets (excluding cash, accounts receivables arising prior to the closing date, and certain other assets). On February 15, 2023, we held the 2023 Special Meeting of Shareholders (the “Special Meeting”) at our corporate offices in Kinderhook, New York, at which a quorum (27,863,899 shares of common stock of the 47,098,476 shares of common stock outstanding) was present in person or represented by proxy. Approval of the Asset Sale to Healgen required the affirmative vote of the holders of a majority of the outstanding shares of the Company’s common stock (par value $0.01) and 26,381,832, or 54.84% of the total outstanding shares of the Company, voted in favor of the Asset Sale to Healgen.

On February 28, 2023, we completed the Asset Sale to Healgen and disposition of substantially all of our assets. In connection with the closing of the Asset Sale to Healgen, and in accordance with the terms of the Asset Purchase Agreement, Healgen paid an aggregate purchase price of $3 million (“Purchase Price”). $300,000 of the Purchase Price is being held back in a retention fund to cover potential indemnification claims during the six months following the close. Net proceeds in the amount of $247,000 were received after satisfaction of 1) a loan with Healgen in the amount of $965,000, 2) the Cherokee LSA, (totaling $1,031,000 for principal and interest through February 27, 2023), 3) the 2019 Cherokee Term Loan (totaling $252,000 for principal and interest through February 27, 2023), 4) delinquent property related taxes in the amount of $193,000 and 5) $12,000 for current property related taxes.

Healgen Loan Promissory Note

On September 28, 2022, we entered into a Loan Promissory Note with Healgen (the “Healgen Loan”) and received gross/net proceeds of $400,000. We utilized $34,000 of the loan proceeds to pay off the Crestmark Line of Credit. On November 15, 2022, we amended the Healgen Loan to address an additional $300,000 in principal received under the Healgen Loan; bringing the total principal due under the Healgen Loan to $700,000. The Healgen Loan was further amended on December 19, 2022 to address an additional $15,000 in principal received under the Healgen Loan; bringing the total principal due under the Healgen Loan to $715,000. (See Note E – Line of Credit and Debt)

On February 28, 2023, with proceeds from the Asset Sale to Healgen, we made a payment in the amount of $965,000 to Healgen for all principal due under the Healgen Loan. Healgen waived all interest due under the Healgen Loan.

ERC Refund

As discussed in Note F, as of March 31, 2023 we were still awaiting the refund for the first quarter of 2021; expected to be $202,000. (See Note M – Subsequent Events for updated information on the ERC refund)

Loans from CEO Melissa Waterhouse

Over the course of the First Quarter 2022, via expense reports, Ms. Waterhouse extended various amounts to the Company for expenses including, but not limited to, amounts for manufacturing materials, services, patent maintenance fees, office supplies, and equipment. Upon closing of the Asset Sale to Healgen, we made a payment to Ms. Waterhouse in the amount of $43,000 to pay all amounts due in connection with these loans.

In addition, at March 31, 2023, we owed Ms. Waterhouse $32,000 in current salary (which is 13 weeks of her non-deferred salary). (see Note M – Subsequent Events for updated information on the Waterhouse loans)

Going Concern

Our financial statements for the First Quarter 2023 were prepared assuming we will continue as a going concern, which assumes the satisfaction of liabilities in the normal course of business. Our current cash balances, together with amounts from accounts receivable, ERC refunds and the receipt of the retention fund associated with the Asset Sale to Healgen, may not be sufficient to fund operations through May 2024. At March 31, 2023, we have Stockholders’ Deficit of $(458,000).

Table of Contents

Debt

Our loan and security agreement and 2019 Term Note with Cherokee for $1,000,000 and $240,000, respectively, expired on February 15, 2022. On June 14, 2022, Cherokee agreed that they would defer the principal amounts due under the Cherokee LSA until February 15, 2023 and that any applicable penalties would also be deferred as long as we remained current on the quarterly interest payments. We used proceeds from the Asset Sale to Healgen to pay off the Cherokee facilities on February 28, 2023.

Throughout most of the year ended December 31, 2022, we had a line of credit with Crestmark Bank. On September 29, 2022, using proceeds from the Healgen Loan, we made a payment to Crestmark Bank in the amount of $34,000 which paid off the balance on the Crestmark LOC. The payoff of the Crestmark Line of Credit resulted in lower interest costs.

As of March 31, 2023, we had the following debt/credit facilities:

Facility	Debtor	Balance as of March 31, 2023		Due Date
Term Loan	Individual		50,000	May 4, 2023⁽¹⁾
Term Loan	Individual		125,000	NA⁽²⁾
Total Debt		$	175,000

(1) See Note M – Subsequent Events for updated information on this loan balance.

(2) The loan agreement was amended on July 13, 2022; one of the revisions made was changing the maturity date from June 15, 2022 to no specific maturity date.

Working Capital Deficit

At March 31, 2023, we were operating at a working capital deficit of $458,000. This compares to a working capital deficit of $2,833,000 at December 31, 2022. The improvement in the working capital deficit is primarily due to the payment of debt with the proceeds from the Asset Sale to Healgen and the retention fund receivable in connection with the Asset Sale to Healgen. We historically satisfied working capital requirements through cash from operations, bank debt and equity financings.

Dividends

We have never paid any dividends on our common shares and anticipate that all future earnings, if any, will be retained for use in our business, and therefore, we do not anticipate paying any cash dividends.

Cash Flow, Outlook/Risk

In the First Quarter 2023, we had net income of $1,881,000 and net cash used in operating activities of $363,000. Our cash position increased to $68,000 at March 31, 2023 from $34,000 at December 31, 2022.

Over the last several years and through February 28, 2023 (the closing date of the Asset Sale to Healgen), we decreased cash requirements by implementing cost cutting initiatives. This included expense reductions in selling and marketing (which included reduced and deferred salaries of a number of employees) and no additional contributions in research and development to develop new products. Such reductions, although necessary to maintain operations, were not compatible with growing or even maintaining our business both in the short and the long term. Our cash position has deteriorated, and continued to deteriorate, due to gross losses, fixed labor and overhead costs and payments required under our debt facilities.

We believed the losses we reported over the last several years and most recently the significant loss reported for in the year ended December 31, 2022 would continue as (i) our primary business (onsite drugs of abuse tests) has become a commoditized market and we cannot compete with the low pricing offered by our competitors who manufacture outside of the U.S. and (ii) we have not been able to obtain new business to replace the significant loss of business from our largest customer.

Table of Contents

Over the last several years, we have been able to access loans from shareholders and raise funds via private equity financings. As time went on and the financial results continued to deteriorate, these options were no longer available. Ms. Waterhouse also extended loans to the Company and deferred her salary.

Given the above, on December 19, 2022, we agreed, subject to the approval of our shareholders, to sell substantially all of our operating assets to Healgen (excluding cash, accounts receivables and certain other assets). We closed on the Asset Sale to Healgen on February 28, 2023.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to provide the information required by this item.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer (Principal Executive Officer)/Chief Financial Officer (Principal Financial Officer), together with other members of management, has reviewed and evaluated the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 Rule 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based on this review and evaluation, our Principal Executive Officer/Principal Financial Officer concluded that our disclosure controls and procedures are effective to ensure that material information relating to the Company is recorded, processed, summarized, and reported in a timely manner.

(b) Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the last quarterly period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

See Part I, Item 1, Note D in the Notes to interim condensed Financial Statements included in this report for a description of pending legal proceedings in which we may be a party.

Item 1A. Risk Factors

There have been no material changes to our risk factors set forth in Part I, Item 1A, in our Annual Report on Form 10-K for the year ended December 31, 2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None that have not been previously disclosed in a Current Report on Form 8-K.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits

31.1/31.2		Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer/Chief Financial Officer

32.1/32.2		Certification of the Chief Executive Officer/Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101		The following materials from our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in XBRL (Extensible Business Reporting Language): (i) Condensed Balance Sheets, (ii) Condensed Statements of Income (iii) Statements of Change in Stockholders’ Equity, (iv) Condensed Statements of Cash Flows, and (v) Notes to Condensed Financial Statements.

Table of Contents

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AMERICAN BIO MEDICA CORPORATION (Registrant)

	By:	/s/ Melissa A. Waterhouse
		Melissa A. Waterhouse
		Chief Executive Officer (Principal Executive Officer) Principal Financial Officer Principal Accounting Officer

Dated: June 12, 2023

EX-31.1 2 abmc_ex311.htm CERTIFICATION abmc_ex311.htm

EXHIBIT 31.1/EXHIBIT 31.2

CERTIFICATION

I, Melissa A. Waterhouse, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of American Bio Medica Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Melissa A. Waterhouse
Melissa A. Waterhouse Chief Executive Officer (Principal Executive Officer) Principal Financial Officer Principal Accounting Officer

Date: June 12, 2023

EX-32.1 3 abmc_ex321.htm CERTIFICATION abmc_ex321.htm

EXHIBIT 32.1/EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of American Bio Medica Corporation (the “Company”) on Form 10-Q for the period ending March 31, 2023 as filed with the Securities and Exchange Commission on June 12, 2023 (the “Report”), I, Melissa A. Waterhouse, Chief Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ Melissa A. Waterhouse
	Melissa A. Waterhouse Chief Executive Officer (Principal Executive Officer) Principal Financial Officer Principal Accounting Officer

	June 12, 2023

EX-101.SCH 4 abmc-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - Statements of Changes in Stockholders Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - Basis of Reporting link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - Net Income (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - LitigationLegal Matters link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - Employee Retention Credit link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - Asset Sale to Healgen link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - Stock Options and Warrants link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - Changes in Stockholders Deficit link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - Basis of Reporting (Policies) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - Net Income (Loss) Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - Stock Options and Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - Net Income (Loss) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - Employee Retention Credit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - Asset Sale to Healgen (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - Stock Options and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - Stock Options and Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000038 - Disclosure - Changes in Stockholders Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000039 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 000040 - Disclosure - Income Taxes (Details 1) link:presentationLink link:calculationLink link:definitionLink 000041 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000042 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 abmc-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Interactive Data Current Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code Security 12b Title Trading Symbol City Area Code Local Phone Number Condensed Balance Sheets Current assets Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of $2,000 at March 31, 2023 and at December 31, 2022 Inventory, net of allowance of $0 at March 31, 2023 and $235,000 at December 31, 2022 Employee retention credit receivable Retention fund receivable-asset sale Prepaid expenses and other current assets Total current assets [Assets, Current] Property, plant and equipment, net Right of use asset - operating leases Other assets Total assets [Assets] LIABILITIES AND STOCKHOLDERS' (DEFICIT) Current liabilities Accounts payable Accrued expenses and other current liabilities Right of use liability - operating leases Wages payable Current portion of long-term debt Total current liabilities [Liabilities, Current] Right of use liability - operating leases [Right of use liability - operating leases] Total liabilities [Liabilities] COMMITMENTS AND CONTINGENCIES Stockholders' deficit: Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at March 31, 2023 and December 31, 2022 Common stock; par value $.01 per share; 75,000,000 shares authorized; 48,098,476 issued and outstanding at March 31, 2023 and at December 31, 2022 Additional paid-in capital Deficit Total stockholders' (deficit) [Stockholders' Equity Attributable to Parent] Total liabilities and stockholders' (deficit) [Liabilities and Equity] Allowance for doubtful accounts receivable, current Inventory, net of allowance Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Condensed Statements of Operations (Unaudited) Net sales Cost of goods sold Gross profit [Gross Profit] Operating expenses: Research and development Selling and marketing General and administrative Operating expenses [Operating Expenses] Operating loss [Operating Income (Loss)] Other income/ (expense): Loss on asset valuation [Loss on asset valuation] Other income - asset sale [Other income - asset sale] Interest expense [Interest Expense] Other non operating expenses [Other Nonoperating Income (Expense)] Net income / (loss) before tax [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Income tax expense Net income / (loss) [Net Income (Loss) Attributable to Parent] Basic and diluted income / (loss) per common share Weighted average number of shares outstanding - basic & diluted Statements of Changes in Stockholders Deficit (Unaudited) Statement [Table] Statement [Line Items] Statement Equity Components [Axis] Common Stock Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Balance, shares [Shares, Issued] Balance, amount Shares issued in connection with Landmark consulting agreement, shares Shares issued in connection with Landmark consulting agreement, amount Net loss Balance, shares Balance, amount Condensed Statements of Cash Flows (Unaudited) Cash flows from operating activities: Net income / (loss) Adjustments to reconcile net income / (loss) to net cash used in operating activities: Depreciation and amortization Asset Sale to Healgen [Gain (Loss) on Disposition of Other Assets] Provision for bad debt Consulting fee paid with restricted stock Changes in: Accounts receivable Inventory [Increase (Decrease) in Inventories] Prepaid expenses and other current assets [Increase (Decrease) in Prepaid Expense and Other Assets] Right of use asset Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses and other current liabilities [Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities] Right of use liability [Right-of-Use Asset Obtained in Exchange for Finance Lease Liability] Wages payable [Increase (Decrease) in Employee Related Liabilities] Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] Cash Flows from investing activities Business Sale, net proceeds Net cash provided by investing activities [Net Cash Provided by (Used in) Investing Activities] Cash flows from financing activities: Payments on debt financing [Repayments of Debt] Proceeds from debt financing Proceeds from lines of credit Payments on lines of credit [Repayments of Lines of Credit] Net cash provided by / (used in) financing activities [Net Cash Provided by (Used in) Financing Activities] Net change in cash and cash equivalents [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect] Cash and cash equivalents - beginning of period [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] Cash and cash equivalents - end of period Supplemental disclosures of cash flow information Non-Cash transactions: Non-Cash transactions: Consulting fee paid with restricted stock Cash paid for interest Basis of Reporting Basis of Reporting Basis of Accounting [Text Block] Inventory Inventory Inventory Disclosure [Text Block] Property, Plant and Equipment Property, Plant and Equipment Property, Plant and Equipment Disclosure [Text Block] Accrued Expenses Accrued Expenses Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Net Income (Loss) Per Common Share Net Income / (Loss) Per Common Share LitigationLegal Matters Litigation/Legal Matters Debt Debt Debt Disclosure [Text Block] Employee Retention Credit Employee Retention Credit [Employee Retention Credit] Asset Sale to Healgen Asset Sale to Healgen [Asset Sale to Healgen] Stock Options and Warrants Stock Options and Warrants [Stock Options and Warrants] Changes in Stockholders Deficit Changes in Stockholders' Deficit Income Taxes Income Taxes Income Tax Disclosure [Text Block] Subsequent Events Subsequent Events Subsequent Events [Text Block] Recently Adopted Accounting Standards Accounting Standards Issued Not Yet Adopted Inventory Schedule of Inventory, Current [Table Text Block] Property, plant and equipment Accrued Expenses [Accrued Expenses] Net Income / (Loss) Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Debt Schedule of Long-Term Debt Instruments [Table Text Block] EX-101.CAL 6 abmc-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 7 abmc-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 8 abmc-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2023	Jun. 12, 2023
Cover [Abstract]
Entity Registrant Name	AMERICAN BIO MEDICA CORPORATION
Entity Central Index Key	0000896747
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		48,098,476
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	0-28666
Entity Incorporation State Country Code	NY
Entity Tax Identification Number	14-1702188
Entity Interactive Data Current	Yes
Entity Address Address Line 1	122 Smith Road
Entity Address City Or Town	Kinderhook
Entity Address State Or Province	NY
Entity Address Postal Zip Code	12106
Security 12b Title	Common Stock
Trading Symbol	ABMC
City Area Code	518
Local Phone Number	758-8158

XML 10 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 68,000	$ 34,000
Accounts receivable, net of allowance for doubtful accounts of $2,000 at March 31, 2023 and at December 31, 2022	89,000	82,000
Inventory, net of allowance of $0 at March 31, 2023 and $235,000 at December 31, 2022	0	379,000
Employee retention credit receivable	202,000	202,000
Retention fund receivable-asset sale	300,000
Prepaid expenses and other current assets	0	72,000
Total current assets	659,000	769,000
Property, plant and equipment, net	0	466,000
Right of use asset - operating leases	0	13,000
Other assets	0	21,000
Total assets	659,000	1,269,000
Current liabilities
Accounts payable	572,000	760,000
Accrued expenses and other current liabilities	338,000	514,000
Right of use liability - operating leases	0	4,000
Wages payable	32,000	94,000
Current portion of long-term debt	175,000	2,230,000
Total current liabilities	1,117,000	3,602,000
Right of use liability - operating leases	0	6,000
Total liabilities	1,117,000	3,608,000
Stockholders' deficit:
Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at March 31, 2023 and December 31, 2022	0	0
Common stock; par value $.01 per share; 75,000,000 shares authorized; 48,098,476 issued and outstanding at March 31, 2023 and at December 31, 2022	481,000	481,000
Additional paid-in capital	22,403,000	22,403,000
Deficit	(23,342,000)	(25,223,000)
Total stockholders' (deficit)	(458,000)	(2,339,000)
Total liabilities and stockholders' (deficit)	$ 659,000	$ 1,269,000

XML 11 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Condensed Balance Sheets
Allowance for doubtful accounts receivable, current	$ 2,000	$ 2,000
Inventory, net of allowance	$ 0	$ 235,000
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	48,098,476	48,098,476
Common stock, shares outstanding	48,098,476	48,098,476

XML 12 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Condensed Statements of Operations (Unaudited)
Net sales	$ 164,000	$ 351,000
Cost of goods sold	90,000	323,000
Gross profit	74,000	28,000
Operating expenses:
Research and development	28,000	22,000
Selling and marketing	20,000	42,000
General and administrative	238,000	295,000
Operating expenses	286,000	359,000
Operating loss	(212,000)	(331,000)
Other income/ (expense):
Loss on asset valuation	(921,000)	0
Other income - asset sale	3,035,000	0
Interest expense	(21,000)	(48,000)
Other non operating expenses	2,093,000	(48,000)
Net income / (loss) before tax	1,881,000	(379,000)
Income tax expense	0	0
Net income / (loss)	$ 1,881,000	$ (379,000)
Basic and diluted income / (loss) per common share	$ 0.04	$ (0.01)
Weighted average number of shares outstanding - basic & diluted	48,098,476	47,770,698

XML 13 R5.htm IDEA: XBRL DOCUMENT

Statements of Changes in Stockholders Deficit (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2021		47,598,476
Balance, amount at Dec. 31, 2021	$ (944,000)	$ 476,000	$ 22,393,000	$ (22,813,000)
Shares issued in connection with Landmark consulting agreement, shares		500,000
Shares issued in connection with Landmark consulting agreement, amount	15,000	$ 5,000	10,000
Net loss	(379,000)			(379,000)
Balance, shares at Mar. 31, 2022		48,098,476
Balance, amount at Mar. 31, 2022	(1,308,000)	$ 481,000	22,403,000	(24,192,000)
Balance, shares at Dec. 31, 2022		48,098,476
Balance, amount at Dec. 31, 2022	(2,339,000)	$ 481,000	22,403,000	(25,223,000)
Net loss	1,881,000			1,881,000
Balance, shares at Mar. 31, 2023		48,098,476
Balance, amount at Mar. 31, 2023	$ (458,000)	$ 481,000	$ 22,403,000	$ (23,342,000)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 14 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net income / (loss)	$ 1,881,000	$ (379,000)
Adjustments to reconcile net income / (loss) to net cash used in operating activities:
Depreciation and amortization	8,000	13,000
Asset Sale to Healgen	(2,114,000)	0
Provision for bad debt	0	(1,000)
Consulting fee paid with restricted stock	0	15,000
Changes in:
Accounts receivable	(7,000)	186,000
Inventory	0	24,000
Prepaid expenses and other current assets	83,000	(11,000)
Right of use asset	0	9,000
Accounts payable	24,000	161,000
Accrued expenses and other current liabilities	(176,000)	(17,000)
Right of use liability	0	(9,000)
Wages payable	(62,000)	(4,000)
Net cash used in operating activities	(363,000)	(13,000)
Cash Flows from investing activities
Business Sale, net proceeds	247,000	0
Net cash provided by investing activities	247,000	0
Cash flows from financing activities:
Payments on debt financing	(100,000)	0
Proceeds from debt financing	250,000	0
Proceeds from lines of credit	0	462,000
Payments on lines of credit	0	(547,000)
Net cash provided by / (used in) financing activities	150,000	(85,000)
Net change in cash and cash equivalents	34,000	(98,000)
Cash and cash equivalents - beginning of period	34,000	115,000
Cash and cash equivalents - end of period	68,000	17,000
Non-Cash transactions:
Non-Cash transactions: Consulting fee paid with restricted stock	0	15,000
Cash paid for interest	$ 41,000	$ 46,000

XML 15 R7.htm IDEA: XBRL DOCUMENT

Basis of Reporting

3 Months Ended

Mar. 31, 2023

Basis of Reporting

Basis of Reporting

Note A - Basis of Reporting

The Company’s credit facilities with Cherokee Financial, LLC (“Cherokee”) were paid in full with proceeds from the asset sale on February 28, 2023.

Recently Adopted Accounting Standards

Accounting Standards Issued; Not Yet Adopted

XML 16 R8.htm IDEA: XBRL DOCUMENT

Inventory

3 Months Ended

Mar. 31, 2023

Inventory

Inventory

Note B – Inventory

Inventory is comprised of the following:

	March 31, 2023*		December 31, 2022

Raw Materials	$	0	$	444,000
Work In Process		0		110,000
Finished Goods		0		60,000
Allowance for slow moving and obsolete inventory		0		(235,000	)
	$	0	$	379,000

*On February 28, 2023, the Company sold substantially all of its assets to Healgen, including its inventory.

XML 17 R9.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment

3 Months Ended

Mar. 31, 2023

Property, Plant and Equipment

Property, Plant and Equipment

Note C – Property, Plant and Equipment

Property, plant and equipment, is comprised of the following:

	March 31, 2023*		December 31, 2022

Land	$	0	$	102,000
Buildings and improvements		0		1,352,000
Manufacturing and warehouse equipment		0		2,110,000
Office equipment (incl. furniture and fixtures)		0		412,000
		0		3,976,000
Less accumulated depreciation		0		(3,510,000	)
	$	0	$	466,000

*On February 28, 2023, the Company sold substantially all of its assets to Healgen, including its property, plant and equipment.

XML 18 R10.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2023

Accrued Expenses

Accrued Expenses

Note D – Accrued Expenses

Accrued expenses and other current liabilities consisted of the following as of March 31, 2023 and December 31, 2022:

	March 31, 2023		December 31, 2022
Accounting fees	$	16,000	$	87,000
Interest payable		20,000		39,000
Accounts receivable credit balances		0		1,000
Sales tax payable		188,000		188,000
Deferred compensation		114,000		109,000
Other current liabilities		0		90,000
	$	338,000	$	514,000

XML 19 R11.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Common Share

3 Months Ended

Mar. 31, 2023

Net Income (Loss) Per Common Share

Net Income / (Loss) Per Common Share

Note E – Net Income / (Loss) Per Common Share

	March 31, 2023		March 31, 2022
Options		1,690,000		1,937,000
Total		1,690,000		1,937,000

XML 20 R12.htm IDEA: XBRL DOCUMENT

LitigationLegal Matters

3 Months Ended

Mar. 31, 2023

LitigationLegal Matters

Litigation/Legal Matters

Note F – Litigation/Legal Matters

XML 21 R13.htm IDEA: XBRL DOCUMENT

Debt

3 Months Ended

Mar. 31, 2023

Debt

Debt

Note G – Debt

The Company’s Line of Credit and Debt consisted of the following as of March 31, 2023 and December 31, 2022:

	March 31, 2023		December 31, 2022
Loan and Security Agreement with Cherokee Financial, LLC: Secured note executed on February 15, 2015, at a fixed annual interest rate of 8% plus a 1% annual oversight fee, interest and oversight fee paid quarterly with principal due on February 15, 2020. Loan was extended for one year (until February 15, 2021) under the same terms and conditions as the original loan. The loan was further extended in February 2021 to February 15, 2022 with $100,000 added to the loan principal as a penalty and the annual interest rate increased to 10%. Loan was further extended in June 2022 (until February 15, 2023). Loan was paid in full on February 28, 2023.	$	0	$	1,000,000
2019 Term Loan with Cherokee Financial, LLC: Note at an annual fixed interest rate of 18% paid quarterly in arrears and a balloon payment due on February 15, 2020. Loan was extended in February 2020, until February 15, 2021 with a penalty of $20,000 added to the loan principal and, extended again in February 2021 to February 15, 2022 with another penalty of $20,000 added to the loan principal. Loan was extended in June 2022 (until February 15, 2023). Loan was paid in full on February 28, 2023.		0		240,000
November 2020 Shareholder Note: Term loan at 7% interest with the first interest only payment being made on February 4, 2021 and the final interest and $50,000 principal due on November 4, 2023.		50,000		50,000
December 2021 Shareholder Notes: Term loan with one non-affiliated shareholder at 7% interest until the loan is paid in full. Loan was amended to address additional amounts provided under the loan.		125,000		225,000
September 2022 Healgen Loan & Promissory Note: Term Loan with Healgen at a fixed rate of 1% per month compounded monthly. Loan was collateralized by first security interest in receivables, inventory, and all other assets with the exception of assets already encumbered. The Healgen loan was paid in full on February 28, 2023 (the closing of the Asset Sale to Healgen) and all interest was waived by Healgen.		0		715,000
Total Debt	$	175,000	$	2,230,000
Current portion	$	175,000	$	2,230,000

LOAN AND SECURITY AGREEMENT (“LSA”) WITH CHEROKEE FINANCIAL, LLC (“CHEROKEE”)

On February 28, 2023, with proceeds from the Asset Sale to Healgen, the Company paid all amounts due to Cherokee under the LSA for principal and interest.

The Company recognized $13,000 in interest expense related to the Cherokee LSA in the First Quarter 2023 and $25,000 in interest expense related to the Cherokee LSA in the First Quarter 2022

As of March 31, 2023 and December 31, 2022, the balance of the Cherokee LSA was $0 and $1,000,000, respectively.

2019 TERM LOAN WITH CHEROKEE

NOVEMBER 2020 TERM LOAN

DECEMBER 2021 SHAREHOLDER LOANS

One of the loans (in the amount of $25,000) was paid in full on June 13, 2022 along with the final interest payment due.

The Company incurred $4,000 in interest expense related to these loans in the First Quarter 2023 and $1,000 in interest expense related to these loans in the First Quarter 2022.

The balance on these loans was $125,000 on March 31, 2023 and $225,000 at December 31, 2022. (See Note M – Subsequent Events for more information on the December 2021 Shareholder Loans)

SEPTEMBER 2022 HEALGEN LOAN & PROMISSORY NOTE

The balance on the Healgen Loan was $0 at March 31, 2023 and $715,000 at December 31, 2022.

OTHER DEBT INFORMATION

In addition to the debt indicated previously, previous debt facilities (paid in full via refinance or conversion into equity) had financial impact on the First Quarter 2022. More specifically:

LINE OF CREDIT WITH CRESTMARK BANK (“CRESTMARK”)

The Company incurred $0 in interest expense in the First Quarter 2023 and $10,000 in interest expense in the First Quarter 2022.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 22 R14.htm IDEA: XBRL DOCUMENT

Employee Retention Credit

3 Months Ended

Mar. 31, 2023

Employee Retention Credit

Employee Retention Credit

NOTE H – Employee Retention Credit

XML 23 R15.htm IDEA: XBRL DOCUMENT

Asset Sale to Healgen

3 Months Ended

Mar. 31, 2023

Asset Sale to Healgen

Asset Sale to Healgen

Note I – Asset Sale to Healgen

XML 24 R16.htm IDEA: XBRL DOCUMENT

Stock Options and Warrants

3 Months Ended

Mar. 31, 2023

Stock Options and Warrants

Stock Options and Warrants

NOTE J – Stock Options and Warrants

During the First Quarter 2023 and the First Quarter 2022, the Company issued 0 options to purchase shares of common stock.

Stock option activity for the First Quarter 2023 and the First Quarter 2022 is summarized as follows (the figures contained within the tables below have been rounded to the nearest thousand):

	First Quarter 2023						First Quarter 2022
	Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value as of March 31, 2023		Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value as of March 31, 2022
Options outstanding at beginning of year		1,736,000	$	0.12				1,937,000	$	0.13
Granted		0	NA					0	NA
Exercised		0	NA					0	NA
Cancelled/expired		46,000	$	0.26				0	NA
Options outstanding at end of quarter		1,690,000	$	0.12	$	0		1,937,000	$	0.13	$	0
Options exercisable at end of quarter		1,690,000	$	0.12				1,937,000	$	0.13

XML 25 R17.htm IDEA: XBRL DOCUMENT

Changes in Stockholders Deficit

3 Months Ended

Mar. 31, 2023

Changes in Stockholders Deficit

Changes in Stockholders' Deficit

NOTE K – Changes in Stockholders’ Deficit

LANDMARK CONSULTING AGREEMENT

Apart from the initial 500,000 restricted common shares, no additional stock was issued to Landmark and no further amounts were paid to Landmark.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 26 R18.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Mar. 31, 2023

Income Taxes

Income Taxes

Note L- Income Taxes

A reconciliation of the U.S. Federal statutory income tax rate to the effective income tax rate is as follows:

	Quarter Ended March 31, 2023			Quarter Ended March 31, 2022
Tax expense at federal statutory rate	(21%)			(21%)
State tax expense, net of federal tax effect		0	%		0	%
Increase in valuation allowance		21	%		21	%
Effective income tax rate	(0%)			(0%)

Significant components of the Company’s deferred income tax assets are as follows:

	March 31, 2023			December 31, 2022
					13,
Inventory allowance	$	0		$	61,000
Allowance for doubtful accounts		1,000			1,000
Stock based compensation		138,000			149,000
Deferred wages payable		30,000			21,000
Depreciation – Property, Plant & Equipment		0			(19,000	)
Research and development credits		26,000			24,000
Net operating loss carry-forward		2,482,000			2,972,000
Total gross deferred income tax assets		2,677,000			3,209,000
Less deferred income tax assets valuation allowance		(2,677,000	)		(3,209,000	)
Net deferred income tax assets	$	0			0

As of March 31, 2023, the prior three years remain open for examination by the federal or state regulatory agencies for purposes of an audit for tax purposes.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 27 R19.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2023

Subsequent Events

Subsequent Events

Note M – Subsequent Events

ERC Refund

November 2020 Term Loan

Upon receipt of the payment from the IRS, the Company paid the principal balance due ($50,000) on this shareholder loan.

December 2021 Shareholder Loan

Current Salary owed to Melissa Waterhouse

XML 28 R20.htm IDEA: XBRL DOCUMENT

Basis of Reporting (Policies)	3 Months Ended
Basis of Reporting (Policies)	Mar. 31, 2023
Basis of Reporting
Recently Adopted Accounting Standards	ASU 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations, issued in September 2022, requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about obligations outstanding at the end of the reporting period, including a rollforward of those obligations. The guidance does not affect the recognition, measurement or financial statement presentation of supplier finance program obligations. ASU 2022-04 became effective on January 1, 2023. The Company adopted ASU 2022-04 on January 1, 2023 and the adoption did not have an impact on the Company’s financial condition or results of operations as the Company does not (and has not historically) utilized supplier finance programs in connection with the purchase of goods and services. ASU 2016-13, Financial Instruments—Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, issued in June 2016, requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted ASU 2016-13 on January 1, 2023 and the adoption did not have a material impact on the Company’s financial condition or results of operations.
Accounting Standards Issued Not Yet Adopted	ASU 2022-03, Fair Value Measurement (Topic 820), Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, issued in June 2022, clarifies that a contractual restriction on the sale of an equity security is not considered in measuring the security's fair value. The standard also requires certain disclosures for equity securities that are subject to contractual restrictions. ASU 2022-03 becomes effective on January 1, 2024. Early adoption is permitted. The Company is evaluating the impact of ASU 2022-03. Any other new accounting pronouncements recently issued, but not yet effective, have been reviewed and determined to be not applicable or were related to technical amendments or codification. As a result, the adoption of such new accounting pronouncements, when effective, is not expected to have a material effect on the Company’s financial position or results of operations.

XML 29 R21.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

3 Months Ended

Mar. 31, 2023

Inventory

Inventory

	March 31, 2023*		December 31, 2022

Raw Materials	$	0	$	444,000
Work In Process		0		110,000
Finished Goods		0		60,000
Allowance for slow moving and obsolete inventory		0		(235,000	)
	$	0	$	379,000

XML 30 R22.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment (Tables)

3 Months Ended

Mar. 31, 2023

Property, Plant and Equipment

Property, plant and equipment

	March 31, 2023*		December 31, 2022

Land	$	0	$	102,000
Buildings and improvements		0		1,352,000
Manufacturing and warehouse equipment		0		2,110,000
Office equipment (incl. furniture and fixtures)		0		412,000
		0		3,976,000
Less accumulated depreciation		0		(3,510,000	)
	$	0	$	466,000

XML 31 R23.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2023

Accrued Expenses

Accrued Expenses

	March 31, 2023		December 31, 2022
Accounting fees	$	16,000	$	87,000
Interest payable		20,000		39,000
Accounts receivable credit balances		0		1,000
Sales tax payable		188,000		188,000
Deferred compensation		114,000		109,000
Other current liabilities		0		90,000
	$	338,000	$	514,000

XML 32 R24.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Common Share (Tables)

3 Months Ended

Mar. 31, 2023

Net Income (Loss) Per Common Share

Net Income / (Loss) Per Common Share

	March 31, 2023		March 31, 2022
Options		1,690,000		1,937,000
Total		1,690,000		1,937,000

XML 33 R25.htm IDEA: XBRL DOCUMENT

DEBT (Tables)

3 Months Ended

Mar. 31, 2023

Debt

Debt

	March 31, 2023		December 31, 2022
Loan and Security Agreement with Cherokee Financial, LLC: Secured note executed on February 15, 2015, at a fixed annual interest rate of 8% plus a 1% annual oversight fee, interest and oversight fee paid quarterly with principal due on February 15, 2020. Loan was extended for one year (until February 15, 2021) under the same terms and conditions as the original loan. The loan was further extended in February 2021 to February 15, 2022 with $100,000 added to the loan principal as a penalty and the annual interest rate increased to 10%. Loan was further extended in June 2022 (until February 15, 2023). Loan was paid in full on February 28, 2023.	$	0	$	1,000,000
2019 Term Loan with Cherokee Financial, LLC: Note at an annual fixed interest rate of 18% paid quarterly in arrears and a balloon payment due on February 15, 2020. Loan was extended in February 2020, until February 15, 2021 with a penalty of $20,000 added to the loan principal and, extended again in February 2021 to February 15, 2022 with another penalty of $20,000 added to the loan principal. Loan was extended in June 2022 (until February 15, 2023). Loan was paid in full on February 28, 2023.		0		240,000
November 2020 Shareholder Note: Term loan at 7% interest with the first interest only payment being made on February 4, 2021 and the final interest and $50,000 principal due on November 4, 2023.		50,000		50,000
December 2021 Shareholder Notes: Term loan with one non-affiliated shareholder at 7% interest until the loan is paid in full. Loan was amended to address additional amounts provided under the loan.		125,000		225,000
September 2022 Healgen Loan & Promissory Note: Term Loan with Healgen at a fixed rate of 1% per month compounded monthly. Loan was collateralized by first security interest in receivables, inventory, and all other assets with the exception of assets already encumbered. The Healgen loan was paid in full on February 28, 2023 (the closing of the Asset Sale to Healgen) and all interest was waived by Healgen.		0		715,000
Total Debt	$	175,000	$	2,230,000
Current portion	$	175,000	$	2,230,000

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

+ Details

XML 34 R26.htm IDEA: XBRL DOCUMENT

Stock Options and Warrants (Tables)

3 Months Ended

Mar. 31, 2023

Stock Options and Warrants

Stock option/warrant activity

	First Quarter 2023						First Quarter 2022
	Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value as of March 31, 2023		Shares		Weighted Average Exercise Price		Aggregate Intrinsic Value as of March 31, 2022
Options outstanding at beginning of year		1,736,000	$	0.12				1,937,000	$	0.13
Granted		0	NA					0	NA
Exercised		0	NA					0	NA
Cancelled/expired		46,000	$	0.26				0	NA
Options outstanding at end of quarter		1,690,000	$	0.12	$	0		1,937,000	$	0.13	$	0
Options exercisable at end of quarter		1,690,000	$	0.12				1,937,000	$	0.13

XML 35 R27.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

3 Months Ended

Mar. 31, 2023

Income Taxes

Effective income tax rate reconciliation

	Quarter Ended March 31, 2023			Quarter Ended March 31, 2022
Tax expense at federal statutory rate	(21%)			(21%)
State tax expense, net of federal tax effect		0	%		0	%
Increase in valuation allowance		21	%		21	%
Effective income tax rate	(0%)			(0%)

Deferred tax assets and liabilities

	March 31, 2023			December 31, 2022
					13,
Inventory allowance	$	0		$	61,000
Allowance for doubtful accounts		1,000			1,000
Stock based compensation		138,000			149,000
Deferred wages payable		30,000			21,000
Depreciation – Property, Plant & Equipment		0			(19,000	)
Research and development credits		26,000			24,000
Net operating loss carry-forward		2,482,000			2,972,000
Total gross deferred income tax assets		2,677,000			3,209,000
Less deferred income tax assets valuation allowance		(2,677,000	)		(3,209,000	)
Net deferred income tax assets	$	0			0

XML 36 R28.htm IDEA: XBRL DOCUMENT

Inventory (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Inventory
Raw materials	$ 0	$ 444,000
Work in process	0	110,000
Finished goods	0	60,000
Allowance for slow moving and obsolete inventory	0	(235,000)
Inventory, net	$ 0	$ 379,000

XML 37 R29.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment
Land	$ 0	$ 102,000
Buildings and improvements	0	1,352,000
Manufacturing and warehouse equipment	0	2,110,000
Office equipment (incl. furniture and fixtures)	0	412,000
Property, plant and equipment, gross	0	3,976,000
Less accumulated depreciation	0	(3,510,000)
Property, plant and equipment, net	$ 0	$ 466,000

XML 38 R30.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Accrued Expenses
Accounting fees	$ 16,000	$ 87,000
Other current liabilities	0	90,000
Accrued expenses	338,000	514,000
Interest payable	20,000	39,000
Accounts receivable credit balances	0	1,000
Sales tax payable	188,000	188,000
Deferred compensation	$ 114,000	$ 109,000

XML 39 R31.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Common Share (Details) - shares	3 Months Ended
Net Income (Loss) Per Common Share (Details) - shares	Mar. 31, 2023	Mar. 31, 2022
Options	1,690,000	1,937,000
Equity Option [Member]
Options	1,690,000	1,937,000

XML 40 R32.htm IDEA: XBRL DOCUMENT

Debt (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Total debt, net	$ 175,000	$ 2,230,000
Current portion	175,000	2,230,000
Loan and Security Agreement with Cherokee Financial, LLC
Long-term debt, gross	0	1,000,000
2019 Term Loan with Cherokee Financial, LLC
Long-term debt, gross	0	240,000
November 2020 Shareholder Note
Long-term debt, gross	50,000	50,000
December 2021 Shareholder Notes
Long-term debt, gross	125,000	225,000
September 2022 Healgen Loan & Promissory note
Long-term debt, gross	$ 0	$ 715,000

- Definition

Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

XML 41 R33.htm IDEA: XBRL DOCUMENT

Debt (Details Narrative) - USD ($)											1 Months Ended									3 Months Ended
Debt (Details Narrative) - USD ($)	Feb. 09, 2023	Jan. 06, 2023	Sep. 13, 2022	Jul. 13, 2022	Jun. 13, 2022	May 11, 2022	Apr. 14, 2022	Apr. 06, 2022	Dec. 14, 2021	Nov. 04, 2020	Feb. 28, 2023	Dec. 19, 2022	Nov. 15, 2022	Sep. 28, 2022	Feb. 15, 2022	Feb. 28, 2021	Feb. 15, 2021	Feb. 28, 2019	Jun. 29, 2015	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Sep. 29, 2022	Dec. 31, 2021	Mar. 26, 2015
Debt payments																				$ 100,000	$ 0
2019 Cherokee Loan and Security Agreement
Principal balance															$ 240,000		$ 220,000			0		$ 240,000		$ 240,000
Delinquent fee charged															8.00%
Loan amount																		$ 200,000
Interest expense																				4,000	11,000
Penalty																	$ 20,000
Annual interest rate on loan																		18.00%
Loan and Security Agreement with Cherokee Financial, LLC
Delinquent fee charged															8.00%
Loan amount																				0		1,000,000			$ 1,200,000
Interest expense																				13,000	25,000
Penalty															$ 100,000
Annual oversight fee percentage																1.00%
Fixed rate																10.00%
Principal amount															$ 1,000,000
Annual principal reduction payments																				75,000
Increased agreement extension amount																$ 1,000,000
Crestmark Line of Credit
Interest expense																				0	10,000
Initial term																			5 years
Payment for line of credit																							$ 34,000
November 2020 Term Loan
Interest expense																				1,000	1,000
Term Loan										$ 50,000										50,000		50,000
Loan interest rate										7.00%
Extended loan maturity										Feb. 04, 2021
SEPTEMBER 2022 HEALGEN LOAN & PROMISSORY NOTE [Member]
Loan interest rate														1.00%
Debt payments														$ 140,000
Increase in principal loan	$ 965,000	$ 815,000										$ 715,000	$ 700,000
Description of amendment	Under this fourth amendment, the amount of the first payment (due February 15, 2023) was changed to $337,000 with payments of the same amount due on March 15, 2023 and April 15, 2023	Under this third amendment, the amount of the first payment (due February 15, 2023) was changed to $286,000 with payments of the same amount due on March 15, 2023 and April 15, 2023										Under this second amendment, the amount of the first payment was changed to $251,000 with payments of the same amount due on March 15, 2023 and April 15, 2023	Under this first amendment, the loan maturity date was extended to April 15, 2023 and the first payment date was extended to February 15, 2023 and changed to $246,000
Promissory Note														40,000
Total amount														400,000
Payment for line of credit																				34,000
Net proceeds														360,000
Balance of Healgen loan																				0		715,000
Payment to healgen against due amount											$ 965,000
December 2021 Shareholder Loans
Interest expense																				4,000	$ 1,000
Loan interest rate									7.00%
Additional funds														40,000
Loan agreement amount			$ 225,000	$ 200,000	$ 175,000	$ 200,000	$ 125,000	$ 75,000	$ 75,000											$ 125,000		$ 225,000
Increase in principal loan			$ 25,000	$ 25,000		$ 75,000	$ 50,000	$ 25,000						$ 265,000
Principal reduction payment					$ 25,000

XML 42 R34.htm IDEA: XBRL DOCUMENT

Employee Retention Credit (Details Narrative) - USD ($)		3 Months Ended	6 Months Ended
Employee Retention Credit (Details Narrative) - USD ($)	Jun. 02, 2022	Mar. 31, 2021	Jun. 30, 2021	Mar. 31, 2023
Employee Retention Credit
Refund of wages	$ 199,000	$ 202,000	$ 198,000
Claimed as a refund amount	198,000
Refund as interest amount	$ 1,000
Refund Total				$ 202,000

XML 43 R35.htm IDEA: XBRL DOCUMENT

Asset Sale to Healgen (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
Asset Sale to Healgen (Details Narrative) - USD ($)	Feb. 28, 2023	Feb. 15, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Purchase price retention fund to cover potential indemnification claims	$ 300,000
Shares of common stock issued		27,863,899
Shares of common stock outstanding		47,098,476
Common stock par value		$ 0.01	$ 0.01		$ 0.01
Shares of common stock sales description		the Asset Sale to Healgen required the affirmative vote of the holders of a majority of the outstanding shares of the Company’s common stock (par value $0.01). 26,381,832, or 54.84% of the total outstanding shares of the Company, voted in favor of the Asset Sale to Healgen. 1,476,077, or 3.06% of the total outstanding shares, voted against the Asset Sale to Healgen. 5,990, or 0.01% of the total shares outstanding, withheld voting on the Asset Sale to Healgen.
Total consideration for sale of assets	3,000,000		$ (2,114,000)	$ 0
Net proceed	247,000
Net proceed from loans	965,000
Property related taxes	193,000
Current property related taxes	12,000
Cherokee LSA [Member]
Principal amount for interest	1,031,000
Cherokee Term Loan [Member]
Principal amount for interest	$ 252,000

XML 44 R36.htm IDEA: XBRL DOCUMENT

Stock Options and Warrants (Details) - Equity Option [Member] - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Shares, beginning balance	1,736,000	1,937,000
Granted	0	0
Share exercised	0	0
Cancelled	46,000	0
Shares, ending balance	1,690,000	1,937,000
Option Exercisable qat end of quarter	1,690,000	1,937,000
Options outstanding at end of quarter Aggregate Intrinsic	$ 0	$ 0
Weighted average exercise price, beginning balance	0.12	0.13
Weighted average exercise price, cancelled/expired	0.26	0
Weighted average exercise price, ending balance	0.12	0.13
Weighted average exercise price, exercisable	$ 0.12	$ 0.13

XML 45 R37.htm IDEA: XBRL DOCUMENT

Stock Options and Warrants (Details Narrative) - Equity Option [Member] - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share based payment	$ 0	$ 0
Unrecognized share based payment expense related to stock options	$ 0

XML 46 R38.htm IDEA: XBRL DOCUMENT

Changes in Stockholders Deficit (Details Narrative) - LANDMARK CONSULTING AGREEMENT [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Restricted shares	500,000
Warrant to purchase	2,750,000
Gross proceeds	96,250,000,000
common shares \| $ / shares	$ 0.035
Additional restricted shares	250,000
Initial restricted common stock shares	500,000

XML 47 R39.htm IDEA: XBRL DOCUMENT

Income Taxes (Details)	3 Months Ended
Income Taxes (Details)	Mar. 31, 2023	Mar. 31, 2022
Income Taxes
Tax expense at federal statutory rate	(21.00%)	(21.00%)
State tax expense, net of federal tax effect	0.00%	0.00%
Increase in valuation allowance	21.00%	21.00%
Effective income tax rate	0.00%	0.00%

XML 48 R40.htm IDEA: XBRL DOCUMENT

Income Taxes (Details 1) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Income Taxes
Inventory allowance	$ 0	$ 61,000
Allowance for doubtful accounts	1,000	1,000
Stock based compensation	138,000	149,000
Deferred wages payable	30,000	21,000
Depreciation - property, plant and equipment	0	(19,000)
Research and development credits	26,000	24,000
Net operating loss carry-forward	2,482,000	2,972,000
Total gross deferred income tax assets	2,677,000	3,209,000
Less deferred income tax assets valuation allowance	(2,677,000)	(3,209,000)
Net deferred income tax assets	$ 0	$ 0

XML 49 R41.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative) - USD ($)	3 Months Ended
Income Taxes (Details Narrative) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Income Taxes
Net deferred income tax assets valuation allowance	$ 2,677,000		$ 3,209,000
Valuation allowance, deferred tax asset, change in amount	532,000	$ 91,000
Research and development	26,000
Operating loss carryforwards	$ 11,427,000
Expire date	expire in 2022 and continue to expire through 2038
Carry overs Operating losses	100.00%
Carry overs Operating losses taxabale income percentage	80.00%

XML 50 R42.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Apr. 17, 2023	Mar. 31, 2023
Consulting services, amount		$ 12,000
Deferred compensation		92,000
November 2020 Term Loan [Member]
Principal loan amount		50,000
Melissa Waterhouse [Member]
Principal loan amount		32,000
December 2021 Shareholder Loan [Member]
Principal loan amount		25,000
Balance due on Short term loan to shareholders		175,000
ERC Refund [Member]
ERC refund amount		$ 202,000
Subsequent Event [Member]
Payment received from IRS	$ 2,000
Payment received	$ 156,000

XML 51 abmc_10q_htm.xml IDEA: XBRL DOCUMENT 0000896747 2023-01-01 2023-03-31 0000896747 us-gaap:SubsequentEventMember 2023-04-01 2023-04-17 0000896747 abmc:ERCRefundMember 2023-01-01 2023-03-31 0000896747 abmc:DecemberTwoThousandTwentyOneShareholderLoanMember 2023-03-31 0000896747 abmc:NovemberTwoThousandTwentyTermLoanMember 2023-03-31 0000896747 abmc:MelissaWaterhouseMember 2023-03-31 0000896747 abmc:LANDMARKCONSULTINGAGREEMENTMember 2023-01-01 2023-03-31 0000896747 us-gaap:StockOptionMember 2023-03-31 0000896747 us-gaap:StockOptionMember 2022-03-31 0000896747 us-gaap:StockOptionMember 2022-12-31 0000896747 us-gaap:StockOptionMember 2021-12-31 0000896747 2023-02-15 0000896747 2023-02-01 2023-02-15 0000896747 2023-02-01 2023-02-28 0000896747 abmc:CherokeeTermLoanMember 2023-02-01 2023-02-28 0000896747 abmc:CherokeeLSAMember 2023-02-01 2023-02-28 0000896747 2021-01-01 2021-06-30 0000896747 2022-06-01 2022-06-02 0000896747 2021-01-01 2021-03-31 0000896747 abmc:SeptemberTwentyTwentyTwoLoanHealgenLoanAndPromissoryNoteMember 2023-02-01 2023-02-28 0000896747 abmc:SeptemberTwentyTwentyTwoLoanHealgenLoanAndPromissoryNoteMember 2022-12-31 0000896747 abmc:SeptemberTwentyTwentyTwoLoanHealgenLoanAndPromissoryNoteMember 2023-03-31 0000896747 abmc:SeptemberTwentyTwentyTwoLoanHealgenLoanAndPromissoryNoteMember 2022-09-28 0000896747 abmc:December2021ShareholderLoansMember 2022-06-01 2022-06-13 0000896747 abmc:SeptemberTwentyTwentyTwoLoanHealgenLoanAndPromissoryNoteMember 2022-12-01 2022-12-19 0000896747 abmc:SeptemberTwentyTwentyTwoLoanHealgenLoanAndPromissoryNoteMember 2023-02-01 2023-02-09 0000896747 abmc:SeptemberTwentyTwentyTwoLoanHealgenLoanAndPromissoryNoteMember 2023-01-01 2023-01-06 0000896747 abmc:SeptemberTwentyTwentyTwoLoanHealgenLoanAndPromissoryNoteMember 2022-11-01 2022-11-15 0000896747 abmc:December2021ShareholderLoansMember 2022-09-01 2022-09-28 0000896747 abmc:December2021ShareholderLoansMember 2022-09-01 2022-09-13 0000896747 abmc:December2021ShareholderLoansMember 2022-07-01 2022-07-13 0000896747 abmc:December2021ShareholderLoansMember 2022-05-01 2022-05-11 0000896747 abmc:December2021ShareholderLoansMember 2022-04-01 2022-04-14 0000896747 abmc:December2021ShareholderLoansMember 2022-04-01 2022-04-06 0000896747 abmc:December2021ShareholderLoansMember 2022-09-13 0000896747 abmc:December2021ShareholderLoansMember 2022-07-13 0000896747 abmc:December2021ShareholderLoansMember 2022-06-13 0000896747 abmc:December2021ShareholderLoansMember 2022-05-11 0000896747 abmc:December2021ShareholderLoansMember 2022-04-14 0000896747 abmc:December2021ShareholderLoansMember 2022-04-06 0000896747 abmc:December2021ShareholderLoansMember 2021-12-14 0000896747 abmc:December2021ShareholderLoansMember 2022-12-31 0000896747 abmc:December2021ShareholderLoansMember 2023-03-31 0000896747 abmc:December2021ShareholderLoansMember 2022-09-28 0000896747 abmc:SeptemberTwentyTwentyTwoLoanHealgenLoanAndPromissoryNoteMember 2022-09-01 2022-09-28 0000896747 abmc:December2021ShareholderLoansMember 2021-12-01 2021-12-14 0000896747 abmc:November2020TermLoanMember 2020-11-01 2020-11-04 0000896747 abmc:November2020TermLoanMember 2022-12-31 0000896747 abmc:November2020TermLoanMember 2023-03-31 0000896747 abmc:November2020TermLoanMember 2020-11-04 0000896747 abmc:CrestmarkLineOfCreditMember 2022-09-29 0000896747 abmc:CrestmarkLineOfCreditMember 2015-06-01 2015-06-29 0000896747 abmc:CherokeeFinancialLlcMember 2021-02-01 2021-02-28 0000896747 abmc:TwentyNineteenCherokeeLoanAndSecurityAgreementMember 2019-02-01 2019-02-28 0000896747 abmc:TwentyNineteenCherokeeLoanAndSecurityAgreementMember 2021-02-01 2021-02-15 0000896747 abmc:December2021ShareholderLoansMember 2022-01-01 2022-03-31 0000896747 abmc:December2021ShareholderLoansMember 2023-01-01 2023-03-31 0000896747 abmc:November2020TermLoanMember 2023-01-01 2023-03-31 0000896747 abmc:November2020TermLoanMember 2022-01-01 2022-03-31 0000896747 abmc:TwentyNineteenCherokeeLoanAndSecurityAgreementMember 2023-01-01 2023-03-31 0000896747 abmc:TwentyNineteenCherokeeLoanAndSecurityAgreementMember 2022-01-01 2022-03-31 0000896747 abmc:CrestmarkLineOfCreditMember 2022-01-01 2022-03-31 0000896747 abmc:CrestmarkLineOfCreditMember 2023-01-01 2023-03-31 0000896747 abmc:CherokeeFinancialLlcMember 2022-01-01 2022-03-31 0000896747 abmc:CherokeeFinancialLlcMember 2023-01-01 2023-03-31 0000896747 abmc:TwentyNineteenCherokeeLoanAndSecurityAgreementMember 2019-02-28 0000896747 abmc:CherokeeFinancialLlcMember 2015-03-26 0000896747 abmc:TwentyNineteenCherokeeLoanAndSecurityAgreementMember 2022-02-01 2022-02-15 0000896747 abmc:CherokeeFinancialLlcMember 2022-02-01 2022-02-15 0000896747 abmc:TwentyNineteenCherokeeLoanAndSecurityAgreementMember 2022-12-31 0000896747 abmc:TwentyNineteenCherokeeLoanAndSecurityAgreementMember 2023-03-31 0000896747 abmc:TwentyNineteenCherokeeLoanAndSecurityAgreementMember 2022-02-15 0000896747 abmc:TwentyNineteenCherokeeLoanAndSecurityAgreementMember 2021-12-31 0000896747 abmc:TwentyNineteenCherokeeLoanAndSecurityAgreementMember 2021-02-15 0000896747 abmc:CherokeeFinancialLlcMember 2022-12-31 0000896747 abmc:CherokeeFinancialLlcMember 2023-03-31 0000896747 abmc:SeptemberTwoThousandTwentyTwoHealgenAndPromissoryNoteMember 2022-12-31 0000896747 abmc:SeptemberTwoThousandTwentyTwoHealgenAndPromissoryNoteMember 2023-03-31 0000896747 abmc:December2021ShareholderNotesMember 2022-12-31 0000896747 abmc:December2021ShareholderNotesMember 2023-03-31 0000896747 abmc:November2020ShareholderNoteMember 2022-12-31 0000896747 abmc:November2020ShareholderNoteMember 2023-03-31 0000896747 abmc:CherokeeFinancialLlc1Member 2022-12-31 0000896747 abmc:CherokeeFinancialLlc1Member 2023-03-31 0000896747 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0000896747 us-gaap:StockOptionMember 2023-01-01 2023-03-31 0000896747 us-gaap:RetainedEarningsMember 2023-03-31 0000896747 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000896747 us-gaap:CommonStockMember 2023-03-31 0000896747 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000896747 us-gaap:RetainedEarningsMember 2022-12-31 0000896747 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000896747 us-gaap:CommonStockMember 2022-12-31 0000896747 2022-03-31 0000896747 us-gaap:RetainedEarningsMember 2022-03-31 0000896747 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000896747 us-gaap:CommonStockMember 2022-03-31 0000896747 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000896747 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000896747 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000896747 2021-12-31 0000896747 us-gaap:RetainedEarningsMember 2021-12-31 0000896747 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000896747 us-gaap:CommonStockMember 2021-12-31 0000896747 2022-01-01 2022-03-31 0000896747 2022-12-31 0000896747 2023-03-31 0000896747 2023-06-12 iso4217:USD shares iso4217:USD shares pure 0000896747 false --12-31 Q1 2023

2000

0.01

5000000

0.01

75000000

48098476

50000

0.01

10-Q true 2023-03-31 false 0-28666 AMERICAN BIO MEDICA CORPORATION NY 14-1702188 122 Smith Road Kinderhook NY 12106 518 758-8158 Common Stock ABMC Yes Yes Non-accelerated Filer true false false 48098476

68000

34000

2000

89000

82000

235000

379000

202000

300000

72000

659000

769000

466000

13000

21000

659000

1269000

572000

760000

338000

514000

0 4000

32000

94000

175000

2230000

1117000

3602000

0 6000

1117000

3608000

5000000

75000000

48098476

481000

22403000

-23342000

-25223000

-458000

-2339000

659000

1269000

164000

351000

90000

323000

74000

28000

22000

20000

42000

238000

295000

286000

359000

-212000

-331000

921000 0 -3035000 0

21000

48000

2093000

-48000

1881000

-379000

1881000

-379000

0.04 -0.01 48098476 47770698

48098476

481000

22403000

-25223000

-2339000

1881000

48098476

481000

22403000

-23342000

-458000

47598476

476000

22393000

-22813000

-944000

500000 5000 10000 15000

-379000

48098476

481000

22403000

-24192000

-1308000

1881000

-379000

8000

13000

-2114000

-1000

0 15000

-7000

186000

24000

83000

-11000

9000

24000

161000

-176000

-17000

9000

-62000

-4000

-363000

-13000

247000

100000

250000

462000

547000

150000

-85000

34000

-98000

34000

115000

68000

17000

0 15000

41000

46000

Note A - Basis of Reporting The accompanying unaudited interim condensed financial statements of American Bio Medica Corporation (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Regulation S-X. Accordingly, these unaudited interim condensed financial statements do not include all information and footnotes required by U.S. GAAP for complete financial statement presentation. These unaudited interim condensed financial statements should be read in conjunction with audited financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. In the opinion of management, the interim condensed financial statements include all normal, recurring adjustments which are considered necessary for a fair presentation of the financial position of the Company at March 31, 2023, and the results of operations and cash flows for the three month periods ended March 31, 2023 (the “First Quarter 2023”) and March 31, 2022 (the “First Quarter 2022”). Operating results for the First Quarter 2023 are not indicative of results that will be reported for the year ending December 31, 2023 as the Company sold substantially all of its assets on February 28, 2023 to Healgen Scientific, LLC (“Healgen”). Amounts at December 31, 2022 are derived from audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. During the First Quarter 2023, there were no significant changes to the Company’s critical accounting policies, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The preparation of these interim condensed financial statements requires the Company to make estimates and judgments that affect the reported amounts of liabilities, expenses, and related disclosure of contingent liabilities. On an on-going basis, the Company evaluates estimates, including those related to bad debts, income taxes, warranty obligations, contingencies and litigation. The Company bases estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. These unaudited interim condensed financial statements have been prepared assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty. The independent registered public accounting firm’s report on the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, contained an explanatory paragraph regarding the Company’s ability to continue as a going concern. As of the date of this report, the Company’s current cash balances and amounts expected from its receivables (including the Employee retention Credit receivable and the retention (escrow) proceeds from the asset sale) may not be sufficient to fund the Company through May 2024. The Company’s credit facilities with Cherokee Financial, LLC (“Cherokee”) were paid in full with proceeds from the asset sale on February 28, 2023. Recently Adopted Accounting Standards ASU 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations, issued in September 2022, requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about obligations outstanding at the end of the reporting period, including a rollforward of those obligations. The guidance does not affect the recognition, measurement or financial statement presentation of supplier finance program obligations. ASU 2022-04 became effective on January 1, 2023. The Company adopted ASU 2022-04 on January 1, 2023 and the adoption did not have an impact on the Company’s financial condition or results of operations as the Company does not (and has not historically) utilized supplier finance programs in connection with the purchase of goods and services.ASU 2016-13, Financial Instruments—Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, issued in June 2016, requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted ASU 2016-13 on January 1, 2023 and the adoption did not have a material impact on the Company’s financial condition or results of operations. Accounting Standards Issued; Not Yet Adopted ASU 2022-03, Fair Value Measurement (Topic 820), Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, issued in June 2022, clarifies that a contractual restriction on the sale of an equity security is not considered in measuring the security's fair value. The standard also requires certain disclosures for equity securities that are subject to contractual restrictions. ASU 2022-03 becomes effective on January 1, 2024. Early adoption is permitted. The Company is evaluating the impact of ASU 2022-03. Any other new accounting pronouncements recently issued, but not yet effective, have been reviewed and determined to be not applicable or were related to technical amendments or codification. As a result, the adoption of such new accounting pronouncements, when effective, is not expected to have a material effect on the Company’s financial position or results of operations.

ASU 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations, issued in September 2022, requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about obligations outstanding at the end of the reporting period, including a rollforward of those obligations. The guidance does not affect the recognition, measurement or financial statement presentation of supplier finance program obligations. ASU 2022-04 became effective on January 1, 2023. The Company adopted ASU 2022-04 on January 1, 2023 and the adoption did not have an impact on the Company’s financial condition or results of operations as the Company does not (and has not historically) utilized supplier finance programs in connection with the purchase of goods and services.ASU 2016-13, Financial Instruments—Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, issued in June 2016, requires companies to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted ASU 2016-13 on January 1, 2023 and the adoption did not have a material impact on the Company’s financial condition or results of operations.

ASU 2022-03, Fair Value Measurement (Topic 820), Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, issued in June 2022, clarifies that a contractual restriction on the sale of an equity security is not considered in measuring the security's fair value. The standard also requires certain disclosures for equity securities that are subject to contractual restrictions. ASU 2022-03 becomes effective on January 1, 2024. Early adoption is permitted. The Company is evaluating the impact of ASU 2022-03. Any other new accounting pronouncements recently issued, but not yet effective, have been reviewed and determined to be not applicable or were related to technical amendments or codification. As a result, the adoption of such new accounting pronouncements, when effective, is not expected to have a material effect on the Company’s financial position or results of operations.

Note B – Inventory Inventory is comprised of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2023*</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Raw Materials</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">444,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Work In Process</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finished Goods </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Allowance for slow moving and obsolete inventory </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(235,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">379,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> *On February 28, 2023, the Company sold substantially all of its assets to Healgen, including its inventory.

444000

110000

60000

235000

379000

Note C – Property, Plant and Equipment Property, plant and equipment, is comprised of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2023*</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Land</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Buildings and improvements</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,352,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Manufacturing and warehouse equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,110,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Office equipment (incl. furniture and fixtures)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">412,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,976,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less accumulated depreciation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,510,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">466,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> *On February 28, 2023, the Company sold substantially all of its assets to Healgen, including its property, plant and equipment.

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2023*</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Land</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">102,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Buildings and improvements</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,352,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Manufacturing and warehouse equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,110,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Office equipment (incl. furniture and fixtures)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">412,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,976,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Less accumulated depreciation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,510,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">466,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

102000

1352000

2110000

412000

3976000

3510000

466000

Note D – Accrued Expenses Accrued expenses and other current liabilities consisted of the following as of March 31, 2023 and December 31, 2022: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounting fees</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">87,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Interest payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">39,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts receivable credit balances</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Sales tax payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">188,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">188,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Deferred compensation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">114,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">109,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other current liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">90,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">338,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">514,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

16000

87000

20000

39000

0 1000

188000

114000

109000

90000

338000

514000

Note E – Net Income / (Loss) Per Common Share Basic net income / (loss) per common share is calculated by dividing the net income / (loss) by the weighted average number of outstanding common shares during the period. Diluted net income / (loss) per common share includes the weighted average dilutive effect of stock options and warrants. When the Company has a loss, option and warrants are not included as they would be anti-dilutive. In the three months ended March 31, 2023, although the Company had net income, there were no options in the money at March 31, 2023. Potential common shares outstanding as of March 31, 2023 and 2022: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:60%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31, 2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,690,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,937,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,690,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,937,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:60%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">March 31, 2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,690,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,937,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,690,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,937,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

1690000

1937000

1690000

1937000

Note F – Litigation/Legal Matters From time to time, the Company may be involved in immaterial legal proceedings in connection with matters that arise during the normal course of business. While the ultimate outcome of any such immaterial litigation cannot be predicted, if the Company is unsuccessful in defending any such litigation, the resulting financial losses are not expected to have a material adverse effect on the financial position, results of operations or cash flows of the Company.

Note G – Debt The Company’s Line of Credit and Debt consisted of the following as of March 31, 2023 and December 31, 2022: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2023</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31, 2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Loan and Security Agreement with Cherokee Financial, LLC: Secured note executed on February 15, 2015, at a fixed annual interest rate of 8% plus a 1% annual oversight fee, interest and oversight fee paid quarterly with principal due on February 15, 2020. Loan was extended for one year (until February 15, 2021) under the same terms and conditions as the original loan. The loan was further extended in February 2021 to February 15, 2022 with $100,000 added to the loan principal as a penalty and the annual interest rate increased to 10%. Loan was further extended in June 2022 (until February 15, 2023). Loan was paid in full on February 28, 2023.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2019 Term Loan with Cherokee Financial, LLC: Note at an annual fixed interest rate of 18% paid quarterly in arrears and a balloon payment due on February 15, 2020. Loan was extended in February 2020, until February 15, 2021 with a penalty of $20,000 added to the loan principal and, extended again in February 2021 to February 15, 2022 with another penalty of $20,000 added to the loan principal. Loan was extended in June 2022 (until February 15, 2023). Loan was paid in full on February 28, 2023.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">240,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">November 2020 Shareholder Note: Term loan at 7% interest with the first interest only payment being made on February 4, 2021 and the final interest and $50,000 principal due on November 4, 2023.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">December 2021 Shareholder Notes: Term loan with one non-affiliated shareholder at 7% interest until the loan is paid in full. Loan was amended to address additional amounts provided under the loan.</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">225,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">September 2022 Healgen Loan & Promissory Note: Term Loan with Healgen at a fixed rate of 1% per month compounded monthly. Loan was collateralized by first security interest in receivables, inventory, and all other assets with the exception of assets already encumbered. The Healgen loan was paid in full on February 28, 2023 (the closing of the Asset Sale to Healgen) and all interest was waived by Healgen. </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">715,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total Debt</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">175,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,230,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Current portion</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">175,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,230,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>LOAN AND SECURITY AGREEMENT (“LSA”) WITH CHEROKEE FINANCIAL, LLC (“CHEROKEE”) On March 26, 2015, the Company entered into a LSA with Cherokee (the “Cherokee LSA”) in the amount of $1,200,000, which was collateralized by a first security interest in real estate and machinery and equipment. The Cherokee LSA reached maturity on February 15, 2020 with a balance of $900,000 (after 4 principal reduction payments of $75,000 each were made over the course of the initial term). In February 2020, the Cherokee LSA was extended for one year, or until February 15, 2021. No terms of the facility were changed under the February 2020 extension. In February 2021, the Cherokee LSA was further extended for another year, or until February 15, 2022 (the “February 2021 Extension”). Under the February 2021 Extension, the principal of the Cherokee LSA was increased to $1,000,000 to include a $100,000 penalty that was due as a result of the Company being unable to pay back the principal balance to Cherokee on February 15, 2021. The annual interest rate on the Cherokee LSA was also increased to a fixed rate of 10% (the prior fixed rate was 8%) plus a 1% annual oversight fee (that remained unchanged). Interest and the oversight fee were still due quarterly. Under the terms of the February 2021 Extension, if the Company didn’t pay off the principal on or before February 15, 2022, Cherokee could charge an 8% delinquent fee on the principal balance ($1,000,000) on February 15, 2022. The Company was not able to pay off the facility on February 15, 2022; however, on June 14, 2022 Cherokee agreed that they would defer the principal amounts due under the Cherokee LSA until February 15, 2023 and that any applicable penalties would also be deferred as long as the Company remained current on the quarterly interest payments. On February 28, 2023, with proceeds from the Asset Sale to Healgen, the Company paid all amounts due to Cherokee under the LSA for principal and interest. The Company recognized $13,000 in interest expense related to the Cherokee LSA in the First Quarter 2023 and $25,000 in interest expense related to the Cherokee LSA in the First Quarter 2022 As of March 31, 2023 and December 31, 2022, the balance of the Cherokee LSA was $0 and $1,000,000, respectively.2019 TERM LOAN WITH CHEROKEE In February 2019, the Company entered into an agreement with Cherokee under which Cherokee provided the Company with a loan in the amount of $200,000 (the “2019 Cherokee Term Loan”). The annual interest rate under the 2019 Cherokee Term Loan was 18% (fixed) paid quarterly in arrears. In February 2020, the 2019 Cherokee Term Loan was extended for one year, or until February 15, 2021. No terms of the facility were changed under the February 2020 extension. The Company incurred a penalty in the amount of $20,000 which was added to the principal balance of the 2019 Cherokee Term Loan; bringing the principal to $220,000. In February 2021, the 2019 Cherokee Term Loan was further extended to February 15, 2022. Under the terms of this additional extension, the 2019 Cherokee Term Loan was increased to $240,000 to include a $20,000 penalty that was due as a result of the Company being unable to pay back the principal balance to Cherokee on February 15, 2021. In addition, if the Company didn’t pay off the principal on or before February 15, 2022, Cherokee could charge an 8% delinquent fee on the principal balance ($240,000) on February 15, 2022. The Company was not able to pay off the facility on February 15, 2022; however, on June 14, 2022 Cherokee agreed that they would defer the principal amounts due under the 2019 Cherokee Term Loan until February 15, 2023 and that any applicable penalties would also be deferred as long as the Company remained current on the quarterly interest payments. The Company recognized $4,000 in interest expense in the First Quarter 2023 and $11,000 in interest expense in the First Quarter 2022. The Company paid all principal and interest due to Cherokee on February 28, 2023 with proceeds from the Asset Sale to Healgen. The balance of the 2019 Cherokee Term Loan was $0 at March 31, 2023 and $240,000 at December 31, 2022.NOVEMBER 2020 TERM LOAN On November 4, 2020, the Company entered into a loan agreement with an individual shareholder in the principal amount of $50,000. There were no expenses related to the term loan and the interest rate is 7%. The first interest only payment was made on February 4, 2021 and the final interest payment and principal was due on May 4, 2021. On May 4, 2021, the Company extended this loan for another 6 months, or until November 4, 2021. The interest rate and all other terms of the note remained unchanged under this extension. On November 4, 2021, the November 2020 Term Loan was extended again. Under this extension, the principal was due on November 4, 2022. The last interest payment made to the shareholder was in November 2021 and was for the period of August 5, 2021 through November 4, 2021. The shareholder agreed to defer the quarterly interest payments due on the extended facility. The facility was further extended on November 4, 2022, under the same terms and conditions, for another 6 months, or until May 4, 2023. The Company recognized less than $1,000 in interest expense related to the November 2020 Term Loan in the First Quarter 2023 and $1,000 in interest expense in the First Quarter 2022. The balance on the November 2020 Term Loan was $50,000 at March 31, 2023 and December 31, 2022. (See Note M – Subsequent Events for more information on the November 2020 Term Loan)DECEMBER 2021 SHAREHOLDER LOANS On December 14, 2021, the Company entered into Loan Agreements with two non-affiliated shareholders resulting in gross (and net) proceeds of $75,000 as there were no costs associated with the loans. Interest on the loans was 7% per annum until principal and interest were due in full, or until June 15, 2022. The first interest payments were due March 15, 2022 and payment of final interest and principal was due June 15, 2022. One of the loans (in the amount of $25,000) was paid in full on June 13, 2022 along with the final interest payment due. On April 6, 2022, the Company amended the loan with the other non-affiliated shareholder. This amendment (No.1; hereinafter referred to in this paragraph as “Amendment No. 1”) increased the principal due to the shareholder by $25,000; bringing their total principal to $75,000. No other terms of the loan were changed under Amendment No. 1.On April 14, 2022, the loan was amended again (under Amendment No. 2; hereinafter referred to in this paragraph as “Amendment No. 2”) increasing the principal again by $50,000; bringing their total principal to $125,000. No other terms of the loan were changed under Amendment No. 2. On May 11, 2022, the loan was amended again (under Amendment No. 3; hereinafter referred to in this paragraph as “Amendment No. 3”) increasing the principal again by $75,000; bringing their total principal to $200,000. The loan was further amended to include a specific payment schedule based on receipt of anticipated ERC refunds. On June 13, 2022, the Company made a principal reduction payment to this shareholder in the amount of $25,000 from proceeds from the ERC refund received on June 2, 2022; bringing the principal amount owed on the loan to $175,000. On July 13, 2022, the loan was amended again (under Amendment No. 4; hereinafter referred to in this paragraph as “Amendment No. 4”) increasing the principal by $25,000; bringing their total principal to $200,000 again. The loan agreement was also amended to revise the maturity date from June 15, 2022 to no specific maturity date. On September 13, 2022, the loan was amended again (under Amendment No. 5; hereinafter referred to in this paragraph as “Amendment No. 5”) increasing the principal by $25,000; bringing their total principal to $225,000 again. On September 28, 2022, the shareholder provided the Company with additional funds, $40,000, under this loan with the understanding that the amount would be paid back once the Healgen Loan funds were received and there would be no interest charged on this additional amount. This increased the amount due to the shareholder under the facility to $265,000. The Company did pay this additional amount in full on October 4, 2022; bringing the balance of the loan back to $225,000. The Company incurred $4,000 in interest expense related to these loans in the First Quarter 2023 and $1,000 in interest expense related to these loans in the First Quarter 2022. The balance on these loans was $125,000 on March 31, 2023 and $225,000 at December 31, 2022. (See Note M – Subsequent Events for more information on the December 2021 Shareholder Loans)SEPTEMBER 2022 HEALGEN LOAN & PROMISSORY NOTE On September 28, 2022, the Company entered into a Loan and Promissory with Healgen Scientific Limited Liability Company (the “Healgen Loan”) at a fixed rate of 1% per month, (compounded monthly) and received initial gross/net proceeds of $40,000 and subsequent gross/net proceeds of $360,000; for a total of $400,000. The Company utilized $34,000 of the loan proceeds to pay off the Crestmark Line of Credit and the balance was used for working capital. The Healgen Loan was collateralized by a first security interest in the Company’s receivables, inventory, and all other assets with the exception of those assets already encumbered. The first payment under the Healgen Loan was due on January 28, 2023 and was in the amount of $140,000. The Healgen Loan was amended on November 15, 2022 to increase the principal due under the loan to $700,000. Under this first amendment, the loan maturity date was extended to April 15, 2023 and the first payment date was extended to February 15, 2023 and changed to $246,000. The Healgen loan was amended again on December 19, 2022 to increase the principal due under the loan to $715,000. Under this second amendment, the amount of the first payment was changed to $251,000 with payments of the same amount due on March 15, 2023 and April 15, 2023. The Healgen Loan was amended again on January 6, 2023 to increase the principal due under the loan to $815,000. Under this third amendment, the amount of the first payment (due February 15, 2023) was changed to $286,000 with payments of the same amount due on March 15, 2023 and April 15, 2023. No other terms of the Healgen Loan were changed. The Healgen Loan was amended again on February 9, 2023 to increase the principal due under the loan to $965,000. Under this fourth amendment, the amount of the first payment (due February 15, 2023) was changed to $337,000 with payments of the same amount due on March 15, 2023 and April 15, 2023. No other terms of the Healgen Loan were changed.On February 28, 2023, with proceeds from the Asset Sale to Healgen, the Company made a payment in the amount of $965,000 to Healgen for all principal due under the Healgen Loan. Healgen waived all interest due under the Healgen Loan. The balance on the Healgen Loan was $0 at March 31, 2023 and $715,000 at December 31, 2022. OTHER DEBT INFORMATION In addition to the debt indicated previously, previous debt facilities (paid in full via refinance or conversion into equity) had financial impact on the First Quarter 2022. More specifically: LINE OF CREDIT WITH CRESTMARK BANK (“CRESTMARK”) On June 29, 2015, the Company entered into a Loan and Security Agreement (“LSA”) with Crestmark related to a revolving line of credit (the “Crestmark LOC”). The Crestmark LOC was used for working capital and general corporate purposes. Upon completion of the initial 5 year term, the Crestmark LOC automatically renewed for additional one (1) year terms unless notice of termination from the Company was received by Crestmark not less than sixty (60) days prior to the end of the renewal term. On September 29, 2022, the Company made a payment to Crestmark in the amount of $34,000 which paid off the balance on the Crestmark LOC. The Company incurred $0 in interest expense in the First Quarter 2023 and $10,000 in interest expense in the First Quarter 2022.

1000000

240000

50000

125000

225000

715000

175000

2230000

175000

2230000

1200000

75000

1000000 100000 0.10 0.01 0.08 1000000

13000

25000

1000000

200000

0.18 220000 240000

20000

0.08 240000

4000

11000

0 240000 50000 0.07 2021-02-04

1000

50000 75000 0.07 25000 25000 75000 50000 125000 75000 200000 25000 175000 25000 200000 225000 40000 265000

4000

1000

125000 225000 0.01

40000

360000

400000

34000

140000

700000 Under this first amendment, the loan maturity date was extended to April 15, 2023 and the first payment date was extended to February 15, 2023 and changed to $246,000 715000 Under this second amendment, the amount of the first payment was changed to $251,000 with payments of the same amount due on March 15, 2023 and April 15, 2023 815000 Under this third amendment, the amount of the first payment (due February 15, 2023) was changed to $286,000 with payments of the same amount due on March 15, 2023 and April 15, 2023 965000 Under this fourth amendment, the amount of the first payment (due February 15, 2023) was changed to $337,000 with payments of the same amount due on March 15, 2023 and April 15, 2023 965000 0 715000

P5Y

34000

10000

NOTE H – Employee Retention Credit The employee retention credit (“ERC”), as originally enacted on March 27, 2020 by the CARES Act, was a refundable tax credit against certain employment taxes equal to 50% of the qualified wages an eligible employer paid to employees and allowed claims through December 31, 2021 by eligible employers who retained employees during the Covid-19 pandemic. However, in November 2021, the ERC was terminated as of September 30, 2021 instead of December 31, 2021. The maximum qualified wages for each employee under the ERC was $10,000 per quarter. Also, because the Company has 100 or fewer full-time employees, health plan expenses borne by the Company could also be included as qualified wages in addition to salary. In August 2021, the Company’s payroll service provider processed and mailed a Form 941-X to claim a refund in the amount of $202,000 on qualified wages paid in the first quarter of 2021. Due to a change in the Form 941-X, the Company’s payroll service provider did not process and mail its Form 941-X to claim a refund in the amount of $198,000 on qualified wages paid in the second quarter of 2021 until October 28, 2021. The Company was informed that the IRS did not have record of receiving the Company’s Form 941-X for the first quarter of 2021 (which was mailed by the Company’s service provider in August 2021). The Company re-sent the Form 941-X for the first quarter of 2021 via overnight service on December 31, 2021 and the IRS received it on January 5, 2022. This lack of receipt resulted in a delay in receiving the expected refund in the amount of $202,000. On June 2, 2022, the Company received a refund for the second quarter of 2021 in the amount of $199,000. This amount represents the $198,000 claimed as a refund and $1,000 in interest. The Company has had a number of discussions with the IRS and has been given a number of time frames in which the refund for the first quarter of 2021 could be expected. As of March 31, 2023, the Company had not yet received the refund. (See Note M – Subsequent Events for updated information on the ERC refund) 202000 198000 202000 199000 198000 1000 Note I – Asset Sale to Healgen Over the last several years, the Company has retained financial consultants to seek out alternative solutions; most recently in early Fiscal 2022. The consultants were seeking solutions including but not limited to potential mergers, acquisitions, investment in the Company, and strategic relationships. Simultaneously, the Company’s management was seeking alternative solutions and began discussions with Healgen. With the current financial condition of the Company, the Company was not able to find a suitable alternative apart from the Asset Sale to Healgen. After carefully weighing the facts and circumstances associated with the Asset Sale to Healgen as well as alternative courses of action, the Company’s Board of Directors (the “Board”) unanimously concluded that the proposed sale of substantially all of the Company’s assets was the best available alternative to maximize value for shareholders.The Board believes the Company’s status as a fully reporting public company is an asset which may be sufficiently attractive to induce others to enter into business combinations with the Company. The Company is exploring strategic transactions which may result in entering into a new line of business (subject to specific competitive limitations under the Asset Sale to Healgen). The Company believes strategic acquisitions using the Company’s publicly traded stock as transaction consideration could enhance shareholder value. Nonetheless, the Board may later determine to dissolve the Company and distribute any remaining assets to the Company’s shareholders if the Company is unable to make any strategic acquisitions or enter into any strategic transactions. On December 19, 2022, the Company entered into an Asset Purchase Agreement (“APA”) with Healgen, pursuant to which the Company agreed, subject to the approval of its shareholders, to sell substantially all of the Company’s operating assets (excluding its cash, accounts receivables arising prior to the closing date, and certain other assets). The Company submitted the Asset Sale to Healgen to a shareholder vote via a preliminary Proxy Statement filed on December 22, 2022. On January 5, 2023, the Company filed an amendment to its Preliminary Proxy Statement and on January 11, 2023, the Company filed its Definitive Proxy Statement with the SEC. On February 15, 2023, the Company held the 2023 Special Meeting of Shareholders (the “Special Meeting”) at the Company’s corporate offices in Kinderhook, New York, at which a quorum (27,863,899 shares of common stock of the 47,098,476 shares of common stock outstanding) was present in person or represented by proxy. Approval of the Asset Sale to Healgen required the affirmative vote of the holders of a majority of the outstanding shares of the Company’s common stock (par value $0.01). 26,381,832, or 54.84% of the total outstanding shares of the Company, voted in favor of the Asset Sale to Healgen. 1,476,077, or 3.06% of the total outstanding shares, voted against the Asset Sale to Healgen. 5,990, or 0.01% of the total shares outstanding, withheld voting on the Asset Sale to Healgen. Given the majority of total outstanding shares voted in favor of the Asset Sale to Healgen, the Asset Sale to Healgen was approved. On February 28, 2023, the Company completed the Asset Sale to Healgen and disposition of substantially all of the Company’s assets. In connection with the closing of the Asset Sale to Healgen, and in accordance with the terms of the Asset Purchase Agreement, Healgen paid an aggregate purchase price of $3 million (“Purchase Price”). $300,000 of the Purchase Price is being held back in a retention fund to cover potential indemnification claims during the six months following the close. Net proceeds in the amount of $247,000 were received by the Company after satisfaction of 1) a loan with Healgen in the amount of $965,000, 2) the Cherokee LSA, (totaling $1,031,000 for principal and interest through February 27, 2023), 3) the 2019 Cherokee Term Loan (totaling $252,000 for principal and interest through February 27, 2023), 4) delinquent property related taxes in the amount of $193,000 and 5) $12,000 for current property related taxes.

27863899

47098476

the Asset Sale to Healgen required the affirmative vote of the holders of a majority of the outstanding shares of the Company’s common stock (par value $0.01). 26,381,832, or 54.84% of the total outstanding shares of the Company, voted in favor of the Asset Sale to Healgen. 1,476,077, or 3.06% of the total outstanding shares, voted against the Asset Sale to Healgen. 5,990, or 0.01% of the total shares outstanding, withheld voting on the Asset Sale to Healgen.

3000000

300000

247000

965000

1031000 252000 193000

12000

NOTE J – Stock Options and Warrants The Company has two non-statutory stock option plans, the Fiscal 2001 Non-statutory Stock Option Plan (the “2001 Plan”) and the 2013 Equity Compensation Plan (the “2013 Plan”). Both plans have been adopted by the Board of Directors and approved by shareholders. Both the 2001 Plan and the 2013 Plan have options available for future issuance. Any common shares issued as a result of the exercise of stock options would be new common shares issued from our authorized issued shares. During the First Quarter 2023 and the First Quarter 2022, the Company issued 0 options to purchase shares of common stock. Stock option activity for the First Quarter 2023 and the First Quarter 2022 is summarized as follows (the figures contained within the tables below have been rounded to the nearest thousand):<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">First Quarter 2023</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">First Quarter 2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Shares</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Aggregate Intrinsic Value as of March 31, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Shares</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Aggregate Intrinsic Value as of March 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options outstanding at beginning of year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,736,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.12</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,937,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">NA</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">NA</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">NA</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">NA</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cancelled/expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">46,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.26</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">NA</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options outstanding at end of quarter</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,690,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.12</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,937,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercisable at end of quarter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">1,690,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">0.12</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">1,937,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">0.13</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The Company recognized $0 in share based payment expense in the First Quarter 2023 and the First Quarter 2022. At March 31, 2023, there was $0 of unrecognized share based payment expense related to stock options.

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">First Quarter 2023</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">First Quarter 2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Shares</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Aggregate Intrinsic Value as of March 31, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Shares</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;">Aggregate Intrinsic Value as of March 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options outstanding at beginning of year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,736,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.12</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,937,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">NA</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">NA</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">NA</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">NA</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cancelled/expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">46,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.26</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">NA</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:6%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Options outstanding at end of quarter</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,690,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.12</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,937,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0.13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercisable at end of quarter</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">1,690,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">0.12</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">1,937,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">0.13</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"> </td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

1736000

0.12

1937000

0.13

0 0

46000

0.26

1690000

0.12

1937000

0.13

0 1690000

0.12

1937000

0.13

NOTE K – Changes in Stockholders’ Deficit LANDMARK CONSULTING AGREEMENT On March 7, 2022, the Company entered into a Financial Advisory Agreement (the “Agreement”) with Landmark Pegasus, Inc. (‘Landmark”). The Agreement provided that Landmark would provide certain financial advisory services for a minimum period of 3 months (which period commenced on February 28, 2022), and as consideration for these services, the Company would pay Landmark (a) a retainer fee consisting of 500,000 restricted shares of common stock and a warrant to purchase 2.75 million shares of the Company’s common stock at a strike price equal to the average closing price of the Company’s common shares for the 30 days preceding the Agreement, or $0.035 per share, resulting in gross proceeds to the Company in the amount of $96,250. The warrant would vest upon the closing of a transaction involving Landmark or upon the invocation of a “Breakup Fee”. In a subsequent amendment, the terms of the warrant were changed to reflect that the warrant would be issued immediately preceding the closing of a transaction involving Landmark or immediately upon the invocation of the Breakup Fee. In each case, the warrant would vest immediately (i.e. the warrant would be 100% immediately exercisable). The Breakup Fee would be invoked upon the generation of a specific transaction to ABMC which meets certain criteria agreed upon by both the Company and Landmark; which transaction is then rejected by the Company. The Company would also pay to Landmark a “Success Fee” for the consummation of a transaction closing during the term of the Agreement and for 12 months thereafter, between the Company and any party first introduced to the Company by Landmark, or with any party the Company has specifically requested Landmark’s assistance with the transaction. Upon invocation of the Breakup Fee or payment of the Success Fee, the Company would also issue an additional 250,000 restricted shares of the Company’s common stock. In the event that the Company consummated a transaction involving the provision of services to any party introduced to the Company by Landmark or with any party the Company has specifically requested Landmark’s assistance with, the Company would pay Landmark 10% of any revenues received from the transaction, unless this percentage is modified by both the Company and Landmark in writing. There is no material relationship between the Company and Landmark, other than with respect to the Agreement. Apart from the initial 500,000 restricted common shares, no additional stock was issued to Landmark and no further amounts were paid to Landmark.

500000

2750000 0.035 96250000000 250000 500000

Note L- Income Taxes The Company follows ASC 740 “Income Taxes” (“ASC 740”) which prescribes the asset and liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted laws and tax rates that will be in effect when the differences are expected to reverse. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits that are not expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. Under ASC 740, tax benefits are recorded only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon ultimate settlement. Unrecognized tax benefits are tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. With regards to the use of net losses incurred for 2018 and later, such net operating losses have no expiration, while taxable income can only be offset up to 80% of taxable income. Net operating losses incurred prior to 2018 may be fully utilized to offset taxable income.A reconciliation of the U.S. Federal statutory income tax rate to the effective income tax rate is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Quarter EndedMarch 31, 2023</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Quarter EndedMarch 31, 2022</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Tax expense at federal statutory rate </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">(21%)</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;">(21%)</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">State tax expense, net of federal tax effect </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Increase in valuation allowance </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">21</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effective income tax rate </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 3px double;">(0%)</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2" style="BORDER-BOTTOM: 3px double;">(0%)</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Significant components of the Company’s deferred income tax assets are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2023</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31, 2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory allowance</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Allowance for doubtful accounts</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock based compensation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">149,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Deferred wages payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation – Property, Plant & Equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Research and development credits</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net operating loss carry-forward</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,482,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,972,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total gross deferred income tax assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,677,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,209,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less deferred income tax assets valuation allowance </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,677,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,209,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net deferred income tax assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The valuation allowance for net deferred income tax assets as of March 31, 2023 and December 31, 2022 was $2,677,000 and $3,209,000, respectively. The net change in the valuation allowance was $532,000 at March 31, 2023 and $91,000 at March 31, 2022. The Company believes that it is more likely than not that the net deferred tax assets will not be realized. As of March 31, 2023, the prior three years remain open for examination by the federal or state regulatory agencies for purposes of an audit for tax purposes. At March 31, 2023, the Company had Federal net operating loss carry-forwards for income tax purposes of approximately $11,427,000 and research and development credits of $26,000. The Company’s net operating loss carry-forwards began to expire in 2022 and continue to expire through 2038. Net operating losses incurred from 2018 to date have no expiration. In assessing the reliability of deferred income tax assets, management considers whether or not it is more likely than not that some portion or all deferred income tax assets will be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the projected future taxable income and tax planning strategies in making this assessment. The Company’s ability to utilize the operating loss carry-forwards and research and development credits may be subject to an annual limitation in future periods pursuant to Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, if future changes in ownership occur. The Company recognizes potential interest and penalties related to income tax positions as a component of the provision for income taxes on operations. The Company does not anticipate that total unrecognized tax benefits will materially change in the next twelve months.

1 0.80

0.21

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">March 31, 2023</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">December 31, 2022</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Inventory allowance</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">61,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Allowance for doubtful accounts</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock based compensation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">149,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Deferred wages payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation – Property, Plant & Equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Research and development credits</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net operating loss carry-forward</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,482,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,972,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total gross deferred income tax assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,677,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,209,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Less deferred income tax assets valuation allowance </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,677,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,209,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net deferred income tax assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

0 61000

1000

138000

149000

30000

21000

19000

26000

24000

2482000

2972000

2677000

3209000

2677000

3209000

2677000

3209000

532000

91000

11427000

26000

expire in 2022 and continue to expire through 2038

Note M – Subsequent Events ERC Refund The Company has been expecting an ERC refund in the amount of $202,000. On April 17, 2023, the Company received payments in the amount of $156,000 and $2,000 from the IRS. There was not any communication with either of the payments. As of the date of this report, the Company is making efforts to speak with the IRS to determine the reason behind the lower refund being received and to determine if additional payments can be expected. November 2020 Term Loan Upon receipt of the payment from the IRS, the Company paid the principal balance due ($50,000) on this shareholder loan. December 2021 Shareholder Loan Upon receipt of the payment from the IRS, the Company made a payment in the amount of $25,000 on this shareholder loan. As of the date of this report, the balance on the December 2021 Shareholder Loan is $175,000. Current Salary owed to Melissa Waterhouse Upon receipt of the payment from the IRS, the Company made a payment in the amount of $32,000 to Melissa Waterhouse to pay current salary owed. As of the date of this report, the amount due to Melissa Waterhouse for deferred compensation is $92,000. Ms. Waterhouse is also owed $12,000 for consulting services from March 2023 through May 2023.

202000

156000

2000

50000

25000

175000

32000

92000

12000 EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end

XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 108 236 1 false 22 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://abmc.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - Condensed Balance Sheets Sheet http://abmc.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://abmc.com/role/CondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://abmc.com/role/CondensedStatementsOfOperationsUnaudited Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 000005 - Statement - Statements of Changes in Stockholders Deficit (Unaudited) Sheet http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited Statements of Changes in Stockholders Deficit (Unaudited) Statements 5 false false R6.htm 000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 000007 - Disclosure - Basis of Reporting Sheet http://abmc.com/role/BasisOfReporting Basis of Reporting Notes 7 false false R8.htm 000008 - Disclosure - Inventory Sheet http://abmc.com/role/Inventory Inventory Notes 8 false false R9.htm 000009 - Disclosure - Property, Plant and Equipment Sheet http://abmc.com/role/PropertyPlantAndEquipment Property, Plant and Equipment Notes 9 false false R10.htm 000010 - Disclosure - Accrued Expenses Sheet http://abmc.com/role/AccruedExpenses Accrued Expenses Notes 10 false false R11.htm 000011 - Disclosure - Net Income (Loss) Per Common Share Sheet http://abmc.com/role/NetIncomeLossPerCommonShare Net Income (Loss) Per Common Share Notes 11 false false R12.htm 000012 - Disclosure - LitigationLegal Matters Sheet http://abmc.com/role/LitigationlegalMatters LitigationLegal Matters Notes 12 false false R13.htm 000013 - Disclosure - Debt Sheet http://abmc.com/role/Debt Debt Notes 13 false false R14.htm 000014 - Disclosure - Employee Retention Credit Sheet http://abmc.com/role/EmployeeRetentionCredit Employee Retention Credit Notes 14 false false R15.htm 000015 - Disclosure - Asset Sale to Healgen Sheet http://abmc.com/role/AssetSaleToHealgen Asset Sale to Healgen Notes 15 false false R16.htm 000016 - Disclosure - Stock Options and Warrants Sheet http://abmc.com/role/StockOptionsAndWarrants Stock Options and Warrants Notes 16 false false R17.htm 000017 - Disclosure - Changes in Stockholders Deficit Sheet http://abmc.com/role/ChangesInStockholdersDeficit Changes in Stockholders Deficit Notes 17 false false R18.htm 000018 - Disclosure - Income Taxes Sheet http://abmc.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 000019 - Disclosure - Subsequent Events Sheet http://abmc.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 000020 - Disclosure - Basis of Reporting (Policies) Sheet http://abmc.com/role/BasisOfReportingPolicies Basis of Reporting (Policies) Policies 20 false false R21.htm 000021 - Disclosure - Inventory (Tables) Sheet http://abmc.com/role/InventoryTables Inventory (Tables) Tables http://abmc.com/role/Inventory 21 false false R22.htm 000022 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://abmc.com/role/PropertyPlantAndEquipmentTables Property, Plant and Equipment (Tables) Tables http://abmc.com/role/PropertyPlantAndEquipment 22 false false R23.htm 000023 - Disclosure - Accrued Expenses (Tables) Sheet http://abmc.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://abmc.com/role/AccruedExpenses 23 false false R24.htm 000024 - Disclosure - Net Income (Loss) Per Common Share (Tables) Sheet http://abmc.com/role/NetIncomeLossPerCommonShareTables Net Income (Loss) Per Common Share (Tables) Tables http://abmc.com/role/NetIncomeLossPerCommonShare 24 false false R25.htm 000025 - Disclosure - DEBT (Tables) Sheet http://abmc.com/role/DebtTables DEBT (Tables) Tables 25 false false R26.htm 000026 - Disclosure - Stock Options and Warrants (Tables) Sheet http://abmc.com/role/StockOptionsAndWarrantsTables Stock Options and Warrants (Tables) Tables http://abmc.com/role/StockOptionsAndWarrants 26 false false R27.htm 000027 - Disclosure - Income Taxes (Tables) Sheet http://abmc.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://abmc.com/role/IncomeTaxes 27 false false R28.htm 000028 - Disclosure - Inventory (Details) Sheet http://abmc.com/role/InventoryDetails Inventory (Details) Details http://abmc.com/role/InventoryTables 28 false false R29.htm 000029 - Disclosure - Property, Plant and Equipment (Details) Sheet http://abmc.com/role/PropertyPlantAndEquipmentDetails Property, Plant and Equipment (Details) Details http://abmc.com/role/PropertyPlantAndEquipmentTables 29 false false R30.htm 000030 - Disclosure - Accrued Expenses (Details) Sheet http://abmc.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://abmc.com/role/AccruedExpensesTables 30 false false R31.htm 000031 - Disclosure - Net Income (Loss) Per Common Share (Details) Sheet http://abmc.com/role/NetIncomeLossPerCommonShareDetails Net Income (Loss) Per Common Share (Details) Details http://abmc.com/role/NetIncomeLossPerCommonShareTables 31 false false R32.htm 000032 - Disclosure - Debt (Details) Sheet http://abmc.com/role/DebtDetails Debt (Details) Details http://abmc.com/role/Debt 32 false false R33.htm 000033 - Disclosure - Debt (Details Narrative) Sheet http://abmc.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://abmc.com/role/Debt 33 false false R34.htm 000034 - Disclosure - Employee Retention Credit (Details Narrative) Sheet http://abmc.com/role/EmployeeRetentionCreditDetailsNarrative Employee Retention Credit (Details Narrative) Details http://abmc.com/role/EmployeeRetentionCredit 34 false false R35.htm 000035 - Disclosure - Asset Sale to Healgen (Details Narrative) Sheet http://abmc.com/role/AssetSaleToHealgenDetailsNarrative Asset Sale to Healgen (Details Narrative) Details http://abmc.com/role/AssetSaleToHealgen 35 false false R36.htm 000036 - Disclosure - Stock Options and Warrants (Details) Sheet http://abmc.com/role/StockOptionsAndWarrantsDetails Stock Options and Warrants (Details) Details http://abmc.com/role/StockOptionsAndWarrantsTables 36 false false R37.htm 000037 - Disclosure - Stock Options and Warrants (Details Narrative) Sheet http://abmc.com/role/StockOptionsAndWarrantsDetailsNarrative Stock Options and Warrants (Details Narrative) Details http://abmc.com/role/StockOptionsAndWarrantsTables 37 false false R38.htm 000038 - Disclosure - Changes in Stockholders Deficit (Details Narrative) Sheet http://abmc.com/role/ChangesInStockholdersDeficitDetailsNarrative Changes in Stockholders Deficit (Details Narrative) Details http://abmc.com/role/ChangesInStockholdersDeficit 38 false false R39.htm 000039 - Disclosure - Income Taxes (Details) Sheet http://abmc.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://abmc.com/role/IncomeTaxesTables 39 false false R40.htm 000040 - Disclosure - Income Taxes (Details 1) Sheet http://abmc.com/role/IncomeTaxesDetails1 Income Taxes (Details 1) Details http://abmc.com/role/IncomeTaxesTables 40 false false R41.htm 000041 - Disclosure - Income Taxes (Details Narrative) Sheet http://abmc.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://abmc.com/role/IncomeTaxesTables 41 false false R42.htm 000042 - Disclosure - Subsequent Events (Details Narrative) Sheet http://abmc.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://abmc.com/role/SubsequentEvents 42 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 18 fact(s) appearing in ix:hidden were eligible for transformation: abmc:TermLoan, us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:ShareBasedCompensation, us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice - abmc_10q.htm 1 abmc_10q.htm abmc-20230331.xsd abmc-20230331_cal.xml abmc-20230331_def.xml abmc-20230331_lab.xml abmc-20230331_pre.xml abmc_ex311.htm abmc_ex321.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 58 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abmc_10q.htm": { "axisCustom": 0, "axisStandard": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 322, "http://xbrl.sec.gov/dei/2022": 28 }, "contextCount": 108, "dts": { "calculationLink": { "local": [ "abmc-20230331_cal.xml" ] }, "definitionLink": { "local": [ "abmc-20230331_def.xml" ] }, "inline": { "local": [ "abmc_10q.htm" ] }, "labelLink": { "local": [ "abmc-20230331_lab.xml" ] }, "presentationLink": { "local": [ "abmc-20230331_pre.xml" ] }, "schema": { "local": [ "abmc-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 308, "entityCount": 1, "hidden": { "http://abmc.com/20230331": 1, "http://fasb.org/us-gaap/2022": 17, "http://xbrl.sec.gov/dei/2022": 5, "total": 23 }, "keyCustom": 58, "keyStandard": 178, "memberCustom": 17, "memberStandard": 5, "nsprefix": "abmc", "nsuri": "http://abmc.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://abmc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - Accrued Expenses", "menuCat": "Notes", "order": "10", "role": "http://abmc.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - Net Income (Loss) Per Common Share", "menuCat": "Notes", "order": "11", "role": "http://abmc.com/role/NetIncomeLossPerCommonShare", "shortName": "Net Income (Loss) Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - LitigationLegal Matters", "menuCat": "Notes", "order": "12", "role": "http://abmc.com/role/LitigationlegalMatters", "shortName": "LitigationLegal Matters", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - Debt", "menuCat": "Notes", "order": "13", "role": "http://abmc.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "abmc:EmployeeRetentionCreditDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - Employee Retention Credit", "menuCat": "Notes", "order": "14", "role": "http://abmc.com/role/EmployeeRetentionCredit", "shortName": "Employee Retention Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "abmc:EmployeeRetentionCreditDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "abmc:AssetSaleToHealgenDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - Asset Sale to Healgen", "menuCat": "Notes", "order": "15", "role": "http://abmc.com/role/AssetSaleToHealgen", "shortName": "Asset Sale to Healgen", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "abmc:AssetSaleToHealgenDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "abmc:StockOptionsAndWarrantsDisclousureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - Stock Options and Warrants", "menuCat": "Notes", "order": "16", "role": "http://abmc.com/role/StockOptionsAndWarrants", "shortName": "Stock Options and Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "abmc:StockOptionsAndWarrantsDisclousureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - Changes in Stockholders Deficit", "menuCat": "Notes", "order": "17", "role": "http://abmc.com/role/ChangesInStockholdersDeficit", "shortName": "Changes in Stockholders Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "18", "role": "http://abmc.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "19", "role": "http://abmc.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - Condensed Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://abmc.com/role/CondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfAccounting", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - Basis of Reporting (Policies)", "menuCat": "Policies", "order": "20", "role": "http://abmc.com/role/BasisOfReportingPolicies", "shortName": "Basis of Reporting (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfAccounting", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - Inventory (Tables)", "menuCat": "Tables", "order": "21", "role": "http://abmc.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - Property, Plant and Equipment (Tables)", "menuCat": "Tables", "order": "22", "role": "http://abmc.com/role/PropertyPlantAndEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "abmc:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - Accrued Expenses (Tables)", "menuCat": "Tables", "order": "23", "role": "http://abmc.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "abmc:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - Net Income (Loss) Per Common Share (Tables)", "menuCat": "Tables", "order": "24", "role": "http://abmc.com/role/NetIncomeLossPerCommonShareTables", "shortName": "Net Income (Loss) Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - DEBT (Tables)", "menuCat": "Tables", "order": "25", "role": "http://abmc.com/role/DebtTables", "shortName": "DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - Stock Options and Warrants (Tables)", "menuCat": "Tables", "order": "26", "role": "http://abmc.com/role/StockOptionsAndWarrantsTables", "shortName": "Stock Options and Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "27", "role": "http://abmc.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - Inventory (Details)", "menuCat": "Details", "order": "28", "role": "http://abmc.com/role/InventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - Property, Plant and Equipment (Details)", "menuCat": "Details", "order": "29", "role": "http://abmc.com/role/PropertyPlantAndEquipmentDetails", "shortName": "Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - Condensed Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://abmc.com/role/CondensedBalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "abmc:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - Accrued Expenses (Details)", "menuCat": "Details", "order": "30", "role": "http://abmc.com/role/AccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "abmc:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - Net Income (Loss) Per Common Share (Details)", "menuCat": "Details", "order": "31", "role": "http://abmc.com/role/NetIncomeLossPerCommonShareDetails", "shortName": "Net Income (Loss) Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - Debt (Details)", "menuCat": "Details", "order": "32", "role": "http://abmc.com/role/DebtDetails", "shortName": "Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - Debt (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://abmc.com/role/DebtDetailsNarrative", "shortName": "Debt (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2022-02-15_abmc_TwentyNineteenCherokeeLoanAndSecurityAgreementMember", "decimals": "0", "lang": null, "name": "abmc:PrincipalAmountBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "abmc:EmployeeRetentionCreditDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2022-06-01to2022-06-02", "decimals": "0", "first": true, "lang": null, "name": "abmc:RefundOfWages", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - Employee Retention Credit (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://abmc.com/role/EmployeeRetentionCreditDetailsNarrative", "shortName": "Employee Retention Credit (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "abmc:EmployeeRetentionCreditDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2022-06-01to2022-06-02", "decimals": "0", "first": true, "lang": null, "name": "abmc:RefundOfWages", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-02-01to2023-02-28", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeaseIndemnificationPaymentReceived", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - Asset Sale to Healgen (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative", "shortName": "Asset Sale to Healgen (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-02-01to2023-02-28", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeaseIndemnificationPaymentReceived", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2022-12-31_us-gaap_StockOptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - Stock Options and Warrants (Details)", "menuCat": "Details", "order": "36", "role": "http://abmc.com/role/StockOptionsAndWarrantsDetails", "shortName": "Stock Options and Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2022-12-31_us-gaap_StockOptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31_us-gaap_StockOptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - Stock Options and Warrants (Details Narrative)", "menuCat": "Details", "order": "37", "role": "http://abmc.com/role/StockOptionsAndWarrantsDetailsNarrative", "shortName": "Stock Options and Warrants (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31_us-gaap_StockOptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31_abmc_LANDMARKCONSULTINGAGREEMENTMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - Changes in Stockholders Deficit (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://abmc.com/role/ChangesInStockholdersDeficitDetailsNarrative", "shortName": "Changes in Stockholders Deficit (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31_abmc_LANDMARKCONSULTINGAGREEMENTMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "39", "role": "http://abmc.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - Condensed Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited", "shortName": "Condensed Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "abmc:DeferredTaxAssetsInventoryAllowance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - Income Taxes (Details 1)", "menuCat": "Details", "order": "40", "role": "http://abmc.com/role/IncomeTaxesDetails1", "shortName": "Income Taxes (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "abmc:DeferredTaxAssetsInventoryAllowance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - Income Taxes (Details Narrative)", "menuCat": "Details", "order": "41", "role": "http://abmc.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "abmc:ContractuallySpecifiedServicingFeesAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - Subsequent Events (Details Narrative)", "menuCat": "Details", "order": "42", "role": "http://abmc.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "abmc:ContractuallySpecifiedServicingFeesAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - Statements of Changes in Stockholders Deficit (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited", "shortName": "Statements of Changes in Stockholders Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "strong", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - Condensed Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - Basis of Reporting", "menuCat": "Notes", "order": "7", "role": "http://abmc.com/role/BasisOfReporting", "shortName": "Basis of Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - Inventory", "menuCat": "Notes", "order": "8", "role": "http://abmc.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - Property, Plant and Equipment", "menuCat": "Notes", "order": "9", "role": "http://abmc.com/role/PropertyPlantAndEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abmc_10q.htm", "contextRef": "From2023-01-01to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 22, "tag": { "abmc_AccountingStandardsIssuedNotYetAdopted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Standards Issued Not Yet Adopted" } } }, "localname": "AccountingStandardsIssuedNotYetAdopted", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/BasisOfReportingPolicies" ], "xbrltype": "textBlockItemType" }, "abmc_AccountsReceivableCreditBalancesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accounts receivable credit balances" } } }, "localname": "AccountsReceivableCreditBalancesCurrent", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "abmc_AdditionalFunds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Additional funds" } } }, "localname": "AdditionalFunds", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_AmountpaidForlinecredit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Payment for line of credit]", "verboseLabel": "Payment for line of credit" } } }, "localname": "AmountpaidForlinecredit", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_AmountpaidforLineOfCredit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Payment for line of credit" } } }, "localname": "AmountpaidforLineOfCredit", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_AnnualInterestRateOnLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual interest rate on loan" } } }, "localname": "AnnualInterestRateOnLoan", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "abmc_AnnualOversightFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual oversight fee percentage" } } }, "localname": "AnnualOversightFeePercentage", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "abmc_AssetSaleOtherIncome": { "auth_ref": [], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 11.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Other income - asset sale]", "negatedLabel": "Other income - asset sale" } } }, "localname": "AssetSaleOtherIncome", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "abmc_AssetSaleToHealgenAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asset Sale to Healgen" } } }, "localname": "AssetSaleToHealgenAbstract", "nsuri": "http://abmc.com/20230331", "xbrltype": "stringItemType" }, "abmc_AssetSaleToHealgenDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Asset Sale to Healgen]", "verboseLabel": "Asset Sale to Healgen" } } }, "localname": "AssetSaleToHealgenDisclosureTextBlock", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/AssetSaleToHealgen" ], "xbrltype": "textBlockItemType" }, "abmc_AssetValuationLoss": { "auth_ref": [], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 10.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Loss on asset valuation]", "negatedLabel": "Loss on asset valuation" } } }, "localname": "AssetValuationLoss", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "abmc_BalanceOfHealgenLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Balance of Healgen loan" } } }, "localname": "BalanceOfHealgenLoan", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_BasicAndDilutedIncomeLossPerCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted income / (loss) per common share" } } }, "localname": "BasicAndDilutedIncomeLossPerCommonShare", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "abmc_CarryOversOperatingLosses": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Carry overs Operating losses" } } }, "localname": "CarryOversOperatingLosses", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "abmc_CarryOversOperatingLossesTaxableIncomePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Carry overs Operating losses taxabale income percentage" } } }, "localname": "CarryOversOperatingLossesTaxableIncomePercentage", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "abmc_CherokeeFinancialLlc1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2019 Term Loan with Cherokee Financial, LLC" } } }, "localname": "CherokeeFinancialLlc1Member", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "abmc_CherokeeFinancialLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan and Security Agreement with Cherokee Financial, LLC" } } }, "localname": "CherokeeFinancialLlcMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetails", "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "abmc_CherokeeLSAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cherokee LSA [Member]" } } }, "localname": "CherokeeLSAMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative" ], "xbrltype": "domainItemType" }, "abmc_CherokeeTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cherokee Term Loan [Member]" } } }, "localname": "CherokeeTermLoanMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative" ], "xbrltype": "domainItemType" }, "abmc_ClaimedAsARefundAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Claimed as a refund amount" } } }, "localname": "ClaimedAsARefundAmount", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/EmployeeRetentionCreditDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_CommonSharesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "common shares" } } }, "localname": "CommonSharesPerShare", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/ChangesInStockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "abmc_ConsultingFeePaidWithRestrictedStock": { "auth_ref": [], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Consulting fee paid with restricted stock" } } }, "localname": "ConsultingFeePaidWithRestrictedStock", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abmc_ContractuallySpecifiedServicingFeesAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Consulting services, amount" } } }, "localname": "ContractuallySpecifiedServicingFeesAmount1", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_CrestmarkLineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Crestmark Line of Credit" } } }, "localname": "CrestmarkLineOfCreditMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "abmc_December2021ShareholderLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December 2021 Shareholder Loans" } } }, "localname": "December2021ShareholderLoansMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "abmc_December2021ShareholderNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December 2021 Shareholder Notes" } } }, "localname": "December2021ShareholderNotesMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "abmc_DecemberTwoThousandTwentyOneShareholderLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December 2021 Shareholder Loan [Member]" } } }, "localname": "DecemberTwoThousandTwentyOneShareholderLoanMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "abmc_DeferredTaxAssetsInventoryAllowance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Inventory allowance" } } }, "localname": "DeferredTaxAssetsInventoryAllowance", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "abmc_DelinquentFeeCharged": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Delinquent fee charged" } } }, "localname": "DelinquentFeeCharged", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "abmc_DescriptionOfAmendment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of amendment" } } }, "localname": "DescriptionOfAmendment", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "abmc_ERCRefundMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ERC Refund [Member]" } } }, "localname": "ERCRefundMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "abmc_EarningPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Per Common Share" } } }, "localname": "EarningPerShareAbstract", "nsuri": "http://abmc.com/20230331", "xbrltype": "stringItemType" }, "abmc_EmployeeRetentionCreditDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Employee Retention Credit]", "verboseLabel": "Employee Retention Credit" } } }, "localname": "EmployeeRetentionCreditDisclosureTextBlock", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/EmployeeRetentionCredit" ], "xbrltype": "textBlockItemType" }, "abmc_ExtendedLoanMaturity": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Extended loan maturity" } } }, "localname": "ExtendedLoanMaturity", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "dateItemType" }, "abmc_FixedRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fixed rate" } } }, "localname": "FixedRate", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "abmc_GrossProceedsToTheEntityUnderAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Gross proceeds" } } }, "localname": "GrossProceedsToTheEntityUnderAgreement", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/ChangesInStockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "abmc_IncreaseInPrincipalLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Increase in principal loan" } } }, "localname": "IncreaseInPrincipalLoan", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_IncreasedAgreementExtensionAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Increased agreement extension amount" } } }, "localname": "IncreasedAgreementExtensionAmount", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_LANDMARKCONSULTINGAGREEMENTMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LANDMARK CONSULTING AGREEMENT [Member]" } } }, "localname": "LANDMARKCONSULTINGAGREEMENTMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/ChangesInStockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "abmc_LitigationLegalMattersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LitigationLegal Matters" } } }, "localname": "LitigationLegalMattersAbstract", "nsuri": "http://abmc.com/20230331", "xbrltype": "stringItemType" }, "abmc_LoanAgreementAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Loan agreement amount" } } }, "localname": "LoanAgreementAmount", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_LoanInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan interest rate" } } }, "localname": "LoanInterestRate", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "abmc_MelissaWaterhouseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Melissa Waterhouse [Member]" } } }, "localname": "MelissaWaterhouseMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "abmc_NonCashTransactionsConsultingFeePaidWithRestrictedStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Non-Cash transactions: Consulting fee paid with restricted stock" } } }, "localname": "NonCashTransactionsConsultingFeePaidWithRestrictedStock", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abmc_November2020ShareholderNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "November 2020 Shareholder Note" } } }, "localname": "November2020ShareholderNoteMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "abmc_November2020TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "November 2020 Term Loan" } } }, "localname": "November2020TermLoanMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "abmc_NovemberTwoThousandTwentyTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "November 2020 Term Loan [Member]" } } }, "localname": "NovemberTwoThousandTwentyTermLoanMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "abmc_OpeartingLossCarryForwardExipryNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expire date" } } }, "localname": "OpeartingLossCarryForwardExipryNotes", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "abmc_OptionExercisableqatendofquarter": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Option Exercisable qat end of quarter]", "periodEndLabel": "Option Exercisable qat end of quarter" } } }, "localname": "OptionExercisableqatendofquarter", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/StockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "abmc_OptionsOutstandingAtEndOfQuarterAggregateIntrinsic": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Options outstanding at end of quarter Aggregate Intrinsic]", "periodEndLabel": "Options outstanding at end of quarter Aggregate Intrinsic" } } }, "localname": "OptionsOutstandingAtEndOfQuarterAggregateIntrinsic", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/StockOptionsAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "abmc_PaymentToHealgenAgainstDueAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Payment to healgen against due amount" } } }, "localname": "PaymentToHealgenAgainstDueAmount", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_Penalty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Penalty]", "verboseLabel": "Penalty" } } }, "localname": "Penalty", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_PrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Principal amount" } } }, "localname": "PrincipalAmount", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_PrincipalAmountBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Principal balance" } } }, "localname": "PrincipalAmountBalance", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_PrincipalAmountForInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Principal amount for interest" } } }, "localname": "PrincipalAmountForInterest", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_PrincipalReductionPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Principal reduction payment" } } }, "localname": "PrincipalReductionPayment", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_ProceedsfFromPromissoryNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net proceeds" } } }, "localname": "ProceedsfFromPromissoryNote", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_PropertyRelatedTaxesNonCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Property related taxes" } } }, "localname": "PropertyRelatedTaxesNonCurrent", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_RefundAsInterestAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Refund as interest amount" } } }, "localname": "RefundAsInterestAmount", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/EmployeeRetentionCreditDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_RefundOfWages": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Refund of wages" } } }, "localname": "RefundOfWages", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/EmployeeRetentionCreditDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_RefundTotalExpected": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Refund Total" } } }, "localname": "RefundTotalExpected", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/EmployeeRetentionCreditDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_RetentionFundReceivableAssetSale": { "auth_ref": [], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Retention fund receivable-asset sale" } } }, "localname": "RetentionFundReceivableAssetSale", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "abmc_RightOfUseLiabilitiesOperatingLeasesCurrent": { "auth_ref": [], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Right of use liability - operating leases" } } }, "localname": "RightOfUseLiabilitiesOperatingLeasesCurrent", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "abmc_RightOfUseLiabilitiesOperatingLeasesnoncurrent": { "auth_ref": [], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Right of use liability - operating leases]", "verboseLabel": "Right of use liability - operating leases" } } }, "localname": "RightOfUseLiabilitiesOperatingLeasesnoncurrent", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "abmc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of accrued expenses and other current liabilities.", "label": "[Accrued Expenses]", "verboseLabel": "Accrued Expenses" } } }, "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "abmc_SeptemberTwentyTwentyTwoLoanHealgenLoanAndPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEPTEMBER 2022 HEALGEN LOAN & PROMISSORY NOTE [Member]" } } }, "localname": "SeptemberTwentyTwentyTwoLoanHealgenLoanAndPromissoryNoteMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "abmc_SeptemberTwoThousandTwentyTwoHealgenAndPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "September 2022 Healgen Loan & Promissory note" } } }, "localname": "SeptemberTwoThousandTwentyTwoHealgenAndPromissoryNoteMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "abmc_ShareExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share exercised" } } }, "localname": "ShareExercised", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/StockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "abmc_SharesIssuedInConnectionWithLandmarkConsultingAgreementAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued in connection with Landmark consulting agreement, amount" } } }, "localname": "SharesIssuedInConnectionWithLandmarkConsultingAgreementAmount", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "abmc_SharesIssuedInConnectionWithLandmarkConsultingAgreementShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued in connection with Landmark consulting agreement, shares" } } }, "localname": "SharesIssuedInConnectionWithLandmarkConsultingAgreementShares", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "abmc_StockIssuedDuringPeriodSharesInitialRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial restricted common stock shares" } } }, "localname": "StockIssuedDuringPeriodSharesInitialRestrictedStock", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/ChangesInStockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "abmc_StockIssuedDuringPeriodSharesOther31": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares of common stock sales description" } } }, "localname": "StockIssuedDuringPeriodSharesOther31", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative" ], "xbrltype": "stringItemType" }, "abmc_StockIssuedDuringPeriodSharesRestrictedStockAdditional": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional restricted shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAdditional", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/ChangesInStockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "abmc_StockOptionsAndWarrantsDisclousureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Stock Options and Warrants]", "verboseLabel": "Stock Options and Warrants" } } }, "localname": "StockOptionsAndWarrantsDisclousureTextBlock", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/StockOptionsAndWarrants" ], "xbrltype": "textBlockItemType" }, "abmc_TermLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Term Loan" } } }, "localname": "TermLoan", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "abmc_TwentyNineteenCherokeeLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2019 Cherokee Loan and Security Agreement" } } }, "localname": "TwentyNineteenCherokeeLoanAndSecurityAgreementMember", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "abmc_WarrantPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant to purchase" } } }, "localname": "WarrantPurchase", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/ChangesInStockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "abmc_WeightedAverageNumberOfSharesOutstandingBasicDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of shares outstanding - basic & diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicDiluted", "nsuri": "http://abmc.com/20230331", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://abmc.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "verboseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accrued expenses and other current liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r14", "r358" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r165", "r166" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net of allowance for doubtful accounts of $2,000 at March 31, 2023 and at December 31, 2022" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounting fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r48", "r107" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r6", "r358" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r243", "r244", "r245", "r379", "r380", "r381", "r421" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income / (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r110", "r167", "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for doubtful accounts receivable, current" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Options" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/NetIncomeLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r79", "r91", "r109", "r127", "r153", "r156", "r160", "r170", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r264", "r266", "r272", "r358", "r387", "r388", "r424" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r103", "r112", "r127", "r170", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r264", "r266", "r272", "r358", "r387", "r388", "r424" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "verboseLabel": "Basis of Reporting" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/BasisOfReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r38", "r105", "r346" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r32", "r38", "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "Cash and cash equivalents - end of period", "periodStartLabel": "Cash and cash equivalents - beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r32", "r72" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-Cash transactions:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r379", "r380", "r421" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockOtherSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Shares of common stock outstanding" } } }, "localname": "CommonStockOtherSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative", "http://abmc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r55" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r5", "r358" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock; par value $.01 per share; 75,000,000 shares authorized; 48,098,476 issued and outstanding at March 31, 2023 and at December 31, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Retention Credit" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r25", "r127", "r170", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r272", "r387" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of goods sold" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r54", "r125", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r208", "r215", "r216", "r218" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r80", "r81", "r90", "r130", "r192", "r193", "r194", "r195", "r196", "r198", "r204", "r205", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r214", "r281", "r351", "r352", "r353", "r354", "r355", "r376" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument Axis" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative", "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r3", "r81", "r90", "r219" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r74", "r76", "r192", "r281", "r352", "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Total amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r19", "r130", "r192", "r193", "r194", "r195", "r196", "r198", "r204", "r205", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r214", "r281", "r351", "r352", "r353", "r354", "r355", "r376" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative", "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r19" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Annual principal reduction payments" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Initial term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredCompensationLiabilityCurrent": { "auth_ref": [ "r62", "r63" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred compensation" } } }, "localname": "DeferredCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Total gross deferred income tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r71", "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Research and development credits" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r418" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Net deferred income tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r71", "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carry-forward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "auth_ref": [ "r71", "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.", "label": "Deferred wages payable" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r71", "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Stock based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r71", "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "Allowance for doubtful accounts" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r251" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "[Deferred Tax Assets, Valuation Allowance]", "negatedLabel": "Less deferred income tax assets valuation allowance", "verboseLabel": "Net deferred income tax assets valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails1", "http://abmc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r71", "r419" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "[Deferred Tax Liabilities, Property, Plant and Equipment]", "negatedLabel": "Depreciation - property, plant and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r36", "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r144", "r145", "r146", "r147" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Net Income / (Loss) Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/NetIncomeLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOnFutureEarningsAmount": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The quantified amount of the future effect on earnings.", "label": "ERC refund amount" } } }, "localname": "EffectOnFutureEarningsAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r128", "r247", "r258" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "[Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent]", "negatedLabel": "Tax expense at federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r416", "r420" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Increase in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r416", "r420" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State tax expense, net of federal tax effect" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Wages payable" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r415" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Unrecognized share based payment expense related to stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in Stockholders Deficit" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r55", "r101", "r115", "r116", "r117", "r131", "r132", "r133", "r135", "r140", "r142", "r148", "r171", "r236", "r243", "r244", "r245", "r254", "r255", "r270", "r273", "r274", "r275", "r276", "r277", "r278", "r286", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r283", "r284", "r356" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Right of use asset" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r168", "r169", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r217", "r234", "r268", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r350", "r383", "r384", "r385", "r427", "r428", "r429", "r430", "r431", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument Axis" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/NetIncomeLossPerCommonShareDetails", "http://abmc.com/role/StockOptionsAndWarrantsDetails", "http://abmc.com/role/StockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Office equipment (incl. furniture and fixtures)" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfOtherAssets": { "auth_ref": [ "r375" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of other assets.", "label": "[Gain (Loss) on Disposition of Other Assets]", "terseLabel": "Total consideration for sale of assets", "verboseLabel": "Asset Sale to Healgen" } } }, "localname": "GainLossOnSaleOfOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative", "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r26" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r24", "r127", "r153", "r155", "r159", "r161", "r170", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r272", "r349", "r387" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "[Gross Profit]", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r22", "r78", "r84", "r98", "r153", "r155", "r159", "r161", "r335", "r349" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]", "totalLabel": "Net income / (loss) before tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Operations (Unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r128", "r248", "r249", "r253", "r256", "r259", "r261", "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationPenaltiesExpense": { "auth_ref": [ "r417" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties recognized in the period arising from income tax examinations.", "label": "Penalty" } } }, "localname": "IncomeTaxExaminationPenaltiesExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r129", "r141", "r142", "r152", "r246", "r257", "r260", "r337" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReceivable": { "auth_ref": [ "r88", "r365" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.", "label": "Employee retention credit receivable" } } }, "localname": "IncomeTaxReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r35" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "[Increase (Decrease) in Accounts Payable]", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r35" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r374" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "[Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities]", "verboseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "[Increase (Decrease) in Deferred Compensation]", "verboseLabel": "Deferred compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r35" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "[Increase (Decrease) in Employee Related Liabilities]", "verboseLabel": "Wages payable" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r35" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Inventories]", "verboseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r35" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "[Increase (Decrease) in Prepaid Expense and Other Assets]", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r75", "r86", "r118", "r151", "r280" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r27", "r212", "r221", "r354", "r355" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "[Interest Expense, Debt]", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r121", "r123", "r124" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryAdjustments": { "auth_ref": [ "r44", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.", "label": "Inventory, net of allowance" } } }, "localname": "InventoryAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r366" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r111", "r347", "r358" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, net of allowance of $0 at March 31, 2023 and $235,000 at December 31, 2022", "verboseLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets", "http://abmc.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r45", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "[Inventory Valuation Reserves]", "negatedLabel": "Allowance for slow moving and obsolete inventory" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r367" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Litigation/Legal Matters" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/LitigationlegalMatters" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeaseIndemnificationPaymentReceived": { "auth_ref": [ "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount received for indemnification payment for tax effect other than investment tax credit for operating lease.", "label": "Purchase price retention fund to cover potential indemnification claims" } } }, "localname": "LessorOperatingLeaseIndemnificationPaymentReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r16", "r127", "r170", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r265", "r266", "r267", "r272", "r348", "r387", "r424", "r425" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r10", "r82", "r94", "r358", "r377", "r386", "r422" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "Total liabilities and stockholders' (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r18", "r104", "r127", "r170", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r265", "r266", "r267", "r272", "r358", "r387", "r424", "r425" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r3", "r81", "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loan amount" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r3", "r81", "r92", "r205", "r220", "r352", "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Total debt, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetails", "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r19", "r53" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetails", "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Manufacturing and warehouse equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r122" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by / (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r122" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r32", "r34", "r37" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r23", "r37", "r85", "r97", "r102", "r113", "r114", "r117", "r127", "r134", "r136", "r137", "r138", "r139", "r141", "r142", "r143", "r153", "r155", "r159", "r161", "r170", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r271", "r272", "r349", "r387" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net income / (loss)", "totalLabel": "Net income / (loss)", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited", "http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Adopted Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/BasisOfReportingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income/ (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r153", "r155", "r159", "r161", "r349" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 12.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r282" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of use asset - operating leases" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Reporting" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r108" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r17", "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtCurrent": { "auth_ref": [ "r1", "r2" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.", "label": "Current portion of long-term debt" } } }, "localname": "OtherLongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r28" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 13.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "[Other Nonoperating Income (Expense)]", "totalLabel": "Other non operating expenses" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherResearchAndDevelopmentExpense": { "auth_ref": [ "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other research and development expense.", "label": "[Other Research and Development Expense]", "verboseLabel": "Research and development" } } }, "localname": "OtherResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromLoansReceivable": { "auth_ref": [ "r39", "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount paid or received by the reporting entity associated with purchase (sale or collection) of loans receivable arising from the financing of goods and services.", "label": "Payment received from IRS" } } }, "localname": "PaymentsForProceedsFromLoansReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name Axis" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/ChangesInStockholdersDeficitDetailsNarrative", "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/ChangesInStockholdersDeficitDetailsNarrative", "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r4", "r222" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r4", "r222" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r4", "r358" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at March 31, 2023 and December 31, 2022" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r370" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrincipalAmountOutstandingOnLoansSecuritized": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This is the principal amount outstanding for securitized loans only (across all types of loans).", "label": "Principal loan amount" } } }, "localname": "PrincipalAmountOutstandingOnLoansSecuritized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r372" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from debt financing" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r30", "r376" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from lines of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Net proceed from loans" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherDebt": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from debt classified as other.", "label": "Net proceed" } } }, "localname": "ProceedsFromOtherDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfLoansReceivable": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale of loans receivables arising from the financing of goods and services.", "label": "Payment received" } } }, "localname": "ProceedsFromSaleOfLoansReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": { "auth_ref": [ "r371" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.", "label": "Business Sale, net proceeds" } } }, "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r50", "r343", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/PropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r47", "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r49", "r95", "r336", "r358" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant and equipment, net", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets", "http://abmc.com/role/PropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/PropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r120", "r174" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for bad debt" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock": { "auth_ref": [ "r20" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from owner or affiliate of reporting entity for issuance of shares. Includes, but is not limited to, amount due for award under share-based payment arrangement. Excludes amount due from officer or director.", "label": "Balance due on Short term loan to shareholders" } } }, "localname": "ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r237", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r100", "r287", "r288", "r423" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative", "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative", "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r237", "r287", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r423" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r373" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "[Repayments of Debt]", "negatedLabel": "Payments on debt financing", "verboseLabel": "Debt payments" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited", "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r31", "r376" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "[Repayments of Lines of Credit]", "negatedLabel": "Payments on lines of credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r67", "r99", "r426" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r7", "r60", "r93", "r341", "r342", "r358" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r101", "r131", "r132", "r133", "r135", "r140", "r142", "r171", "r243", "r244", "r245", "r254", "r255", "r270", "r338", "r340" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r119", "r127", "r149", "r150", "r154", "r157", "r158", "r162", "r163", "r164", "r170", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r272", "r335", "r387" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r285", "r356" ], "calculation": { "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "[Right-of-Use Asset Obtained in Exchange for Finance Lease Liability]", "negatedLabel": "Right of use liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r14" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales tax payable" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r19", "r56", "r57", "r58", "r59", "r73", "r74", "r76", "r87", "r352", "r354", "r378" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "verboseLabel": "Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Net Income / (Loss) Per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/NetIncomeLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective income tax rate reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r0", "r11", "r12", "r13" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r64", "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Stock option/warrant activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StockOptionsAndWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotes": { "auth_ref": [ "r83", "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.", "label": "Promissory Note" } } }, "localname": "SeniorNotes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share based payment" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price]", "periodEndLabel": "Weighted average exercise price, exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StockOptionsAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Shares, ending balance", "periodStartLabel": "Shares, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Weighted average exercise price, ending balance", "periodStartLabel": "Weighted average exercise price, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StockOptionsAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted average exercise price, cancelled/expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StockOptionsAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r21", "r55", "r101", "r115", "r116", "r117", "r131", "r132", "r133", "r135", "r140", "r142", "r148", "r171", "r236", "r243", "r244", "r245", "r254", "r255", "r270", "r273", "r274", "r275", "r276", "r277", "r278", "r286", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative", "http://abmc.com/role/ChangesInStockholdersDeficitDetailsNarrative", "http://abmc.com/role/DebtDetails", "http://abmc.com/role/DebtDetailsNarrative", "http://abmc.com/role/NetIncomeLossPerCommonShareDetails", "http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited", "http://abmc.com/role/StockOptionsAndWarrantsDetails", "http://abmc.com/role/StockOptionsAndWarrantsDetailsNarrative", "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Cash Flows (Unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Changes in Stockholders Deficit (Unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r131", "r132", "r133", "r148", "r322" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative", "http://abmc.com/role/ChangesInStockholdersDeficitDetailsNarrative", "http://abmc.com/role/DebtDetails", "http://abmc.com/role/DebtDetailsNarrative", "http://abmc.com/role/NetIncomeLossPerCommonShareDetails", "http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited", "http://abmc.com/role/StockOptionsAndWarrantsDetails", "http://abmc.com/role/StockOptionsAndWarrantsDetailsNarrative", "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Shares of common stock issued" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r55", "r60" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Restricted shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/ChangesInStockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/NetIncomeLossPerCommonShareDetails", "http://abmc.com/role/StockOptionsAndWarrantsDetails", "http://abmc.com/role/StockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r5", "r8", "r9", "r43", "r358", "r377", "r386", "r422" ], "calculation": { "http://abmc.com/role/CondensedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets", "http://abmc.com/role/StatementsOfChangesInStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options and Warrants" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r61", "r126", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r235", "r236", "r269" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Changes in Stockholders' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/ChangesInStockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r279", "r290" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r279", "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type Axis" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r279", "r290" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r289", "r291" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/CondensedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense classified as other.", "label": "Current property related taxes" } } }, "localname": "TaxesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/AssetSaleToHealgenDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r168", "r169", "r217", "r234", "r268", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r383", "r384", "r385", "r427", "r428", "r429", "r430", "r431", "r432", "r433" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/NetIncomeLossPerCommonShareDetails", "http://abmc.com/role/StockOptionsAndWarrantsDetails", "http://abmc.com/role/StockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r252" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation allowance, deferred tax asset, change in amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://abmc.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123386281&loc=SL77919478-209972", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r359": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r361": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r362": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r363": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3095-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3098-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r427": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r428": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r429": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r431": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r432": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r433": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.16)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 59 0001654954-23-007911-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-23-007911-xbrl.zip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end